Mutation	Gene	Genomic	Phenotype category	Effect	Overview report(s)	Primary literature
S477N	S	False	ACE2_host_variant_dependency	 This mutation's measured interaction affinity with ACE2:p.S19P (0.03% minor allele frequency,   found almost exclusively in African/African-Americans in the GnomAD database)  was significantly lower than the predicted value,   indicating that these mutations were not independent. This is consistent with the fact that the ACE2 residue S19   is adjacent to RBD residue S477 in the contact interface.   Barton et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1
K417R	S	False	ACE2_receptor_binding_affinity	 Causes 1.6 fold decrease in KD value for antibody binding of P22A-1D1.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417A	S	False	ACE2_receptor_binding_affinity	 Causes no detectable change in KD value for antibody binding of P22A-1D1.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417E	S	False	ACE2_receptor_binding_affinity	 Causes 2.4 fold decrease in KD value for antibody binding of P22A-1D1.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417N	S	False	ACE2_receptor_binding_affinity	 Causes no detectable change in KD value for antibody binding of P22A-1D1.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417T	S	False	ACE2_receptor_binding_affinity	 Causes no detectable change in KD value for antibody binding of P22A-1D1.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417R	S	False	ACE2_receptor_binding_affinity	 Causes 1.1 fold decrease in KD value for antibody binding of P5A-1D2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417A	S	False	ACE2_receptor_binding_affinity	 Causes no detectable change in KD value for antibody binding of P5A-1D2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417E	S	False	ACE2_receptor_binding_affinity	 Causes no detectable change in KD value for antibody binding of P5A-1D2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417N	S	False	ACE2_receptor_binding_affinity	 Causes no detectable change in KD value for antibody binding of P5A-1D2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417T	S	False	ACE2_receptor_binding_affinity	 Causes no detectable change in KD value for antibody binding of P5A-1D2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417R	S	False	ACE2_receptor_binding_affinity	 Causes 1.8 fold decrease in KD value for antibody binding of P5A-3C8.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417A	S	False	ACE2_receptor_binding_affinity	 Causes 564.8 fold decrease in KD value for antibody binding of P5A-3C8.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417E	S	False	ACE2_receptor_binding_affinity	 Causes 15.9 fold decrease in KD value for antibody binding of P5A-3C8.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417N	S	False	ACE2_receptor_binding_affinity	 Causes 36.9 fold decrease in KD value for antibody binding of P5A-3C8.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417T	S	False	ACE2_receptor_binding_affinity	 Causes 57.1 fold decrease in KD value for antibody binding of P5A-3C8.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417R	S	False	ACE2_receptor_binding_affinity	 Causes 4.4 fold increase in KD value for antibody binding of P2C-1F11.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417A	S	False	ACE2_receptor_binding_affinity	 Causes 2.5 fold decrease in KD value for antibody binding of P2C-1F11.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417E	S	False	ACE2_receptor_binding_affinity	 Causes 10 fold decrease in KD value for antibody binding of P2C-1F11.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417N	S	False	ACE2_receptor_binding_affinity	 Causes 7.5 fold decrease in KD value for antibody binding of P2C-1F11.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417T	S	False	ACE2_receptor_binding_affinity	 Causes 2.9 fold decrease in KD value for antibody binding of P2C-1F11.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417R	S	False	ACE2_receptor_binding_affinity	 Causes 3.3 fold increase in KD value of antibody binding of ACE2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417A	S	False	ACE2_receptor_binding_affinity	 Causes 1.3 fold decrease in KD value of antibody binding of ACE2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417E	S	False	ACE2_receptor_binding_affinity	 Causes 1.7 fold decrease in KD value of antibody binding of ACE2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417N	S	False	ACE2_receptor_binding_affinity	 Causes 1.5 fold decrease in KD value of antibody binding of ACE2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417T	S	False	ACE2_receptor_binding_affinity	 Causes 1.1 fold decrease in KD value of antibody binding of ACE2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
F486S	S	False	ACE2_receptor_binding_affinity	 In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed striking resistance with only 38% neutralization at the highest concentration tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484D	S	False	ACE2_receptor_binding_affinity	 In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed a 4.6x drop in sensitivity.   Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
T345A	S	False	ACE2_receptor_binding_affinity	 In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed a ~4x drop in sensitivity.   Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
G446D	S	False	ACE2_receptor_binding_affinity	 In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed a ~4x drop in sensitivity.   Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
G446V	S	False	ACE2_receptor_binding_affinity	 In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed a ~4x drop in sensitivity.   Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
T345N	S	False	ACE2_receptor_binding_affinity	 In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed a ~4x drop in sensitivity.   Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484D	S	False	ACE2_receptor_binding_affinity	 In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed a ~4x drop in sensitivity.   Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
F486Y	S	False	ACE2_receptor_binding_affinity	 In a soluble human ACE2-Fc receptor decoy inhibition experiment, this mutation showed a ~4x drop in sensitivity.   Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
N501Y	S	False	ACE2_receptor_binding_affinity	 The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the  affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7  fold as measured by surface plasmon resonance.   Barton et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1
H69del, V70del	S	False	ACE2_receptor_binding_affinity	" Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.51x increase in binding (KD) relative to D614G,  mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1"	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
Y144del	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
N501Y	S	False	ACE2_receptor_binding_affinity	" Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G,  mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages  containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1"	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
A570D	S	False	ACE2_receptor_binding_affinity	" Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.18x increase in binding (KD) relative to D614G,  mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1"	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
P681H	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T716I	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.12x decrease in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
S982A	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.3x decrease in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D1118H	S	False	ACE2_receptor_binding_affinity	" Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x increase in binding (KD) relative to D614G,  mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis).  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1"	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L18F	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G.  Compare to increased binding in full Spike variant complements for major lineages  containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D80A	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination showed no change relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D215G	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.19x increase in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L242del, A243del, L244del	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.35x decrease in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
R246I	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
K417N	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
E484K	S	False	ACE2_receptor_binding_affinity	 This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)   using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
A701V	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T20N	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.96x increase in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
P26S	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.58x increase in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D138Y	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.32x increase in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
R190S	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.82x increase in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
K417T	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.28x increase in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
H655Y	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.21x increase in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T1027I	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L5F	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.1x decrease in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T95I	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D253G	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.08x decrease in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L5F, T95I, D253G, E484K, A701V	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.526) showed a 1.78x increase   in binding (KD) relative to D614G, even though each variant independently decreases binding.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
S13I	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.42x increase in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
W152C	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x increase in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L452R	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.66x increase in binding (KD) relative to D614G.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
S13I, W152C, L452R	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.429 aka Epsilon) showed a 2.82x increase   in binding (KD) relative to D614G, indicating a strong marginal effect for L452R.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
"L452R, E484Q	"	S	False	ACE2_receptor_binding_affinity	 Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617) showed a 1.85x increase   in binding (KD) relative to D614G. [exact variant list not provided in manuscript, is inferred fro common knowledge]  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
E484K, N501Y	S	False	ACE2_receptor_binding_affinity	 In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to  ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher  k(on) could result in mass transfer limiting binding, we confirmed that the kinetic  measurement for this variant was not substantially affected by varying levels of  immobilization.  Barton et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1
K417T	S	False	ACE2_receptor_binding_affinity	 The K417T mutation decreased the affinity ~2 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.  Barton et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1
K417N	S	False	ACE2_receptor_binding_affinity	 The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.  Barton et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1
K417N, E484K, N501Y	S	False	ACE2_receptor_binding_affinity	 The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild   type RBD by increasing the k(on) and decreasing the k(off) rate constants.   Barton et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1
K417T, E484K, N501Y	S	False	ACE2_receptor_binding_affinity	 The affinity of the P.1 RBD variants for ACE2 increased by 5.3 fold as measured by surface plasmon resonance relative to wild   type RBD by increasing the k(on) and decreasing the k(off) rate constants.   Barton et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1
K417T, E484K, N501Y	S	False	ACE2_receptor_binding_affinity	 The KD for the pseudotyped P.1-ACE2 interaction is 4.8 nM, showing that binding to P.1 is essentially indistinguishable from B.1.351 (4.0 nM),  which binds with ~19x greater affinity that wild type.  Dejnirattisai et al. (2021) https://doi.org/10.1016/j.cell.2021.03.055	Pokay DB	https://doi.org/10.1016/j.cell.2021.03.055
N501Y, Q677H	S	False	ACE2_receptor_binding_affinity	 Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage  was tested on ACE2.293T cells for ACE2 affinity changes vs D614G alone, showing a ~70%  drop in IC50 (i.e. increased affinity).  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
N501Y	S	False	ACE2_receptor_binding_affinity	 This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,   but combined with the complete set of B.1.1.7    lineage variants no major change vs wild type affnity is observed.   Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1  ~4-fold increase in binding affinity vs wild type.  Motozono et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1  In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike   RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of   interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the   increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501   mutant residue with the ACE2 receptor, which in this strain is increased.  Santos and Passos (2021) https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1"
H69del, V70del, N501Y	S	False	ACE2_receptor_binding_affinity	 This mutation combination causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped   lentivirus, but combined with the complete set of B.1.1.7    lineage variants no major change vs wild type affnity is observed.   Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
S982A	S	False	ACE2_receptor_binding_affinity	 This mutation causes major decrease in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
Y453F	S	False	ACE2_receptor_binding_affinity	 ~4-fold increase in binding affinity vs wild type.  Motozono et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1
L452R	S	False	ACE2_receptor_binding_affinity	 ~1.7-fold increase in binding affinity vs wild type.  Motozono et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1
S494P	S	False	ACE2_receptor_binding_affinity	 Using molecular dynamic simulation, the mildly (~1kcal/mol) enhanced binding energy of this variant is primarily   contributed by Tyr505 (âˆ’4.98 kcal/mol) which is now involved in a strong hydrogen bonding network with Arg393.   Another important energetic contribution comes from the altered orientation of Tyr41 which is now involved with   two hydrogen-bonding interactions with Asp355 and Thr500.   Chakraborty (2021) https://doi.org/10.1016/j.bbrc.2021.01.035	Pokay DB	https://doi.org/10.1016/j.bbrc.2021.01.035
K417N, E484K, N501Y	S	False	ACE2_receptor_binding_affinity	 Studying the key covariants in lineage of concern 501Y.V2,   observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between   immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1  Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).  Tian et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2  The affinity of ACE2 for this mutation combination was twice as high as for wild type.  Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared  to SARS-CoV-1, this factor of 2 is expected to be biologically significant.  Vogel et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1  RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than   wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,   while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds   3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.  Laffeber et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1  Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly   five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).  Ramanathan et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1  This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting  that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30  Collier et al. (2021) https://doi.org/10.1038/s41586-021-03412-7	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;https://doi.org/10.1038/s41586-021-03412-7"
K417N	S	False	ACE2_receptor_binding_affinity	 Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd = 145.1nM vs 56.9nM).  Tian et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2
E484K	S	False	ACE2_receptor_binding_affinity	 Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd = 38.5nM vs 56.9nM).  Tian et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2
K458R	S	False	ACE2_receptor_binding_affinity	 In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
Q498H	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.3 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N501F	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.29 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y453F	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.25 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N501Y	S	False	ACE2_receptor_binding_affinity	 Experimentally, ACE2 binding affinity increased 0.24 fold  Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012  Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding.  Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd = 455 pM vs 1600pM)  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392  Reported 10-fold increase in ACE2 binding vs wildtype (Kd = 0.566nM vs 5.768 nM)  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1  Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd = 13.1nM vs 56.9nM).  Tian et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2  N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.   The additional interactions result in increased affinity of ACE2 for the N501Y mutant,   accounting for its increased infectivity.  Zhu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2  Using Microscale Thermopheresis, this variant binds ACE2 at nearly   two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).  Ramanathan et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1  The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation   sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.  Gamez et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1	Pokay DB	"https://doi.org/10.1016/j.cell.2020.08.012;https://www.biorxiv.org/content/10.1101/2021.01.06.425392;https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1;https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2;https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1"
K417V	S	False	ACE2_receptor_binding_affinity	 ~2-fold loss of binding affinity for the K417V variant relative to WT  Thomson et al. (2021) https://doi.org/10.1016/j.cell.2021.01.037  ~2-fold loss of binding affinity for the K417V variant relative to WT  Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	"https://doi.org/10.1016/j.cell.2021.01.037;https://doi.org/10.1016/j.cell.2020.08.012"
K417V, N439K	S	False	ACE2_receptor_binding_affinity	 N439K creates a new RBD:hACE2 salt bridge while K417V removes one,  making this roughly a neutral combination in terms of binding affinity.  Thomson et al. (2021) https://doi.org/10.1016/j.cell.2021.01.037	Pokay DB	https://doi.org/10.1016/j.cell.2021.01.037
N439K	S	False	ACE2_receptor_binding_affinity	 Enhances RBD:hACE2 affinity approximately 2-fold.  Observed that the N439K mutation results in viral fitness (culture-based) that is  similar or possibly slightly improved relative to the wild-type N439 virus  Thomson et al. (2021) https://doi.org/10.1016/j.cell.2021.01.037	Pokay DB	https://doi.org/10.1016/j.cell.2021.01.037
N439R	S	False	ACE2_receptor_binding_affinity	 Enhances RBD:hACE2 affinity approximately 2-fold.  Thomson et al. (2021) https://doi.org/10.1016/j.cell.2021.01.037	Pokay DB	https://doi.org/10.1016/j.cell.2021.01.037
V483E	S	False	ACE2_receptor_binding_affinity	 Minor variant in initial round of in vitro evolution experiment for ACE2 binding.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
N481Y	S	False	ACE2_receptor_binding_affinity	 Minor variant in initial round of in vitro evolution experiment for ACE2 binding.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
I468T	S	False	ACE2_receptor_binding_affinity	 Minor variant in initial round of in vitro evolution experiment for ACE2 binding, increasing in later rounds.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
V483E	S	False	ACE2_receptor_binding_affinity	 Minor variant in initial round of in vitro evolution experiment for ACE2 binding.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
S494P	S	False	ACE2_receptor_binding_affinity	 Minor variant selected in late rounds of an in vitro evolution experiment for ACE2 binding.  Shown to increase the thermostability but decrease the association rate constant of the RBD to ACE2  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
T385R	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.19 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q493M	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.18 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q414A	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q498Y	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V445K	S	False	ACE2_receptor_binding_affinity	 This is a two point mutation change giving additional fitness later in an in vitro ACE2 affinity evolution experiment.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
T470M	S	False	ACE2_receptor_binding_affinity	 This is a two point mutation change giving additional fitness later in an in vitro ACE2 affinity evolution experiment.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
N354E	S	False	ACE2_receptor_binding_affinity	 Minor variant enriched in an in vitro ACE2 affinity evolution experiment.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
K417F	S	False	ACE2_receptor_binding_affinity	 Minor variant enriched in an in vitro ACE2 affinity evolution experiment.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
V367W	S	False	ACE2_receptor_binding_affinity	 Minor variant enriched in an in vitro ACE2 affinity evolution experiment.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
E484R	S	False	ACE2_receptor_binding_affinity	 This is a two point mutation change giving this position the highest possible fitness, has higher affinity than circulating E484K variant.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392 Experimentally, ACE2 binding affinity increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.06.425392;https://doi.org/10.1016/j.cell.2020.08.012"
Q498F	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N501V	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367W	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q493A	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505W	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L517M	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q493Y	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367A	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N501W	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527M	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K528F	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I358F	S	False	ACE2_receptor_binding_affinity	"Among the first selected variants in an in vitro evolution experiment for ACE2 binding, described as ""stabilizing"" since it nicely fits inside the hydrophobic pocket formed in the RBD domain. Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392 Experimentally, ACE2 binding affinity increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012"	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.06.425392;https://doi.org/10.1016/j.cell.2020.08.012"
N501T	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V503K	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V503M	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S383E	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452K	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K458D	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N460K	S	False	ACE2_receptor_binding_affinity	 Selected with increasing proportion during in vitro evolution of Spike against ACE2 receptor  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392  Experimentally, ACE2 binding affinity increased 0.09 fold  Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.06.425392;https://doi.org/10.1016/j.cell.2020.08.012"
E484K, Q498R, N501Y	S	False	ACE2_receptor_binding_affinity	 Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen  bond and salt bridge to Q42 and D38 of ACE2, forming a strong network of new interactions  supporting the impact of these residues on affinity.   Q498R alone appears to decrease ACE2 binding.  The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50-  fold relative to WT.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
Q498R, N501Y	S	False	ACE2_receptor_binding_affinity	 Y501 makes a pi interaction with Y41 and places R498 to make a hydrogen bond and salt bridge to Q42 and D38 of ACE2,   forming a strong network of new interactions supporting the impact of these residues on affinity. Q498R alone appears   to decrease ACE2 binding. The synergism of Q498R with N501Y (and E484K) increases ACE2 binding by ~50- fold relative   to WT. The extent of affinity increase with Q498R and N501Y is not exactly quantified, as E484K always emerged with   this duo during in vitro evolution.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
S477D	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F490K	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L518S	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I332E	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R346H	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S359Q	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V362T	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S366N	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K378R	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y453K	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S530N	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N334D	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R346Y	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I358W	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367F	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
E406Q	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N440K	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452Q	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I468M	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q498W	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y508H	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527Q	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K529V	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N331T	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I332P	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L335E	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L335P	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P337D	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G339D	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R346T	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R346V	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A363W	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369M	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S383T	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
T385E	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452M	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K458E	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N460R	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S477N	S	False	ACE2_receptor_binding_affinity	 Experimentally, ACE2 binding affinity increased 0.06 fold  Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012  Increased affinity for ACE2: clade in Australia 2020-05-27 onward, clade in Europe 2020-08-08 onward  Modelling shows flexible region in Spike RBD with residue S477 having the greatest rotational flexibility.  Singh et al. (2021) https://assets.researchsquare.com/files/rs-106969/v2_stamped.pdf  Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding, with increasing proportion in subsequent rounds.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	"https://doi.org/10.1016/j.cell.2020.08.012;https://assets.researchsquare.com/files/rs-106969/v2_stamped.pdf;https://www.biorxiv.org/content/10.1101/2021.01.06.425392"
N448S	S	False	ACE2_receptor_binding_affinity	 Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
G446R	S	False	ACE2_receptor_binding_affinity	 Selected as minor variant in later rounds of an in vitro evolution experiment for ACE2 binding.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
I468V	S	False	ACE2_receptor_binding_affinity	 Selected as minor variant in later rounds of an in vitro evolution experiment for ACE2 binding.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
T478S	S	False	ACE2_receptor_binding_affinity	 Selected as minor variant in later rounds of an in vitro evolution experiment for ACE2 binding.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
G446R	S	False	ACE2_receptor_binding_affinity	 Selected as minor variant in later rounds of an in vitro evolution experiment for ACE2 binding.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
F490S	S	False	ACE2_receptor_binding_affinity	 Among the first selected minor variants in an in vitro evolution experiment for ACE2 binding.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.06.425392
S477P	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V483L	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
E484K	S	False	ACE2_receptor_binding_affinity	Among the first selected variants in an in vitro evolution experiment for ACE2 binding. Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392 Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.06.425392;https://doi.org/10.1016/j.cell.2020.08.012"
F490Y	S	False	ACE2_receptor_binding_affinity	 Selected as minor variant in later rounds of an in vitro evolution experiment for ACE2 binding.  Zahradnik et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.06.425392  Experimentally, ACE2 binding affinity increased 0.06 fold  Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.06.425392;https://doi.org/10.1016/j.cell.2020.08.012"
Q493F	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S494H	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L517R	S	False	ACE2_receptor_binding_affinity	Experimentally, ACE2 binding affinity increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L270F	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*02:01.  Agerer et al. (2021) https://www.science.org/doi/epdf/10.1126/sciimmunol.abg6461	Pokay DB	https://www.science.org/doi/epdf/10.1126/sciimmunol.abg6461
L270F	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type B*08:01.  Agerer et al. (2021) https://www.science.org/doi/epdf/10.1126/sciimmunol.abg6461	Pokay DB	https://www.science.org/doi/epdf/10.1126/sciimmunol.abg6461
Y453F	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*24:02.  Motozono et al. (2021) https://www.cell.com/cell-host-microbe/pdfExtended/S1931-3128(21)00284-5	Pokay DB	https://www.cell.com/cell-host-microbe/pdfExtended/S1931-3128(21)00284-5
R765L	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DRB1*15:01.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
R765L	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DQB1*05:03.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
R765L	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA class 2.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
M177I	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DQB1*02:01.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
M177I	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DQB1*05:03.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
M177I	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DQB1*05:02.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
M177I	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DQB1*02:02.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
M177I	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type C*07:02.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
M177I	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DPB1*04:01.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
D80A	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA class 2.  Riou et al. (2021) https://www.science.org/doi/epdf/10.1126/scitranslmed.abj6824	Pokay DB	https://www.science.org/doi/epdf/10.1126/scitranslmed.abj6824
R765L	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type DRB1*04:04.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
M177I	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA class 2.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
M177I	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DRB1*16:01.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
M177I	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DRB1*07:01.  de Silva et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1
D215G	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DRB1*13:02.  Riou et al. (2021) https://www.science.org/doi/epdf/10.1126/scitranslmed.abj6824	Pokay DB	https://www.science.org/doi/epdf/10.1126/scitranslmed.abj6824
D215G	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DRB1*03:02.  Riou et al. (2021) https://www.science.org/doi/epdf/10.1126/scitranslmed.abj6824	Pokay DB	https://www.science.org/doi/epdf/10.1126/scitranslmed.abj6824
D215G	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA type DRB1*03:01.  Riou et al. (2021) https://www.science.org/doi/epdf/10.1126/scitranslmed.abj6824	Pokay DB	https://www.science.org/doi/epdf/10.1126/scitranslmed.abj6824
P272L	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type B*08:01.  Dolton et al. (2021) https://www.medrxiv.org/content/10.1101/2021.06.21.21259010v2.full.pdf	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.06.21.21259010v2.full.pdf
P272L	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*02:01.  Dolton et al. (2021) https://www.medrxiv.org/content/10.1101/2021.06.21.21259010v2.full.pdf	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.06.21.21259010v2.full.pdf
L18F	S	False	T_cell_evasion	" This mutation causes reduced recognition by CD4 positive t-cells in people with HLA class 2. 	Riou et al. (2021) https://www.science.org/doi/epdf/10.1126/scitranslmed.abj6824"	Pokay DB	https://www.science.org/doi/epdf/10.1126/scitranslmed.abj6824
D1118H	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD4 positive t-cells in people with HLA class 2.  Reynolds et al. (2021) https://www.science.org/doi/epdf/10.1126/science.abh1282	Pokay DB	https://www.science.org/doi/epdf/10.1126/science.abh1282
L452R	S	False	T_cell_evasion	 This mutation causes reduced recognition by CD8 positive t-cells in people with HLA type A*24:02.  Motozono et al. (2021) https://www.cell.com/cell-host-microbe/pdfExtended/S1931-3128(21)00284-5	Pokay DB	https://www.cell.com/cell-host-microbe/pdfExtended/S1931-3128(21)00284-5
F486V	S	False	T_cell_evasion	 This mutation causes a greater than 100x fold change in IC50 of Ensovibep.  Rothenberger et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.03.429164v4	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.03.429164v4
F486L	S	False	T_cell_evasion	 This mutation causes a greater than 100x fold change in IC50 of Ensovibep.  Rothenberger et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.03.429164v4	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.03.429164v4
N234Q	S	False	T_cell_evasion	 This mutation causes a greater than 16.2x fold change in IC50 of Ensovibep.  Rothenberger et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.03.429164v4	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.03.429164v4
D80A	S	False	T_cell_evasion	 One individual of 30 in the study, with HLA supertype HLA*A24:02, had a linear epitope that overlaps this variant of concern.  Redd et al. (2021) https://www.medrxiv.org/content/10.1101/2021.02.11.21251585v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.02.11.21251585v1
Y453F	S	False	T_cell_evasion	 The induction level of IFN-gamma expression by the Y453F derivative in two different A*24:02 convalescent sera   donor plasma (linear epitope NYNYLYRLF 448,456) was significantly lower.  Motozono et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf
L452R	S	False	T_cell_evasion	 L452R derivative virus did not induce IFN-gamma expression even at the highest concentration tested (10 nM) in two different A*24:02 convalescent sera   donor plasma (linear epitope NYNYLYRLF 448,456).  Motozono et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1.full.pdf
D1118H	S	False	T_cell_evasion	 Mutation is predicted to lose the T cell epitope for people carrying DRB1*0301 and DRB1*0401,   but not for example in those who are DRB1*0701 or DRB1*1501 who would be predicted to show an enhanced response.  This is also observed in a study of 26 each post-infection and post first dose HCWs.  Reynolds et al. (2021) https://doi.org/10.1126/science.abh1282	Pokay DB	https://doi.org/10.1126/science.abh1282
E484K	S	False	T_cell_evasion	 Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did   not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared   to have no substantial or differential impact on T cell responses.  Reynolds et al. (2021) https://doi.org/10.1126/science.abh1282	Pokay DB	https://doi.org/10.1126/science.abh1282
N501Y	S	False	T_cell_evasion	 Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide.  When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,   T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p = 0.0286).   Furthermore, the T cell response to the spike N501Y mutation common to all three of the current VOC was ablated.  Reynolds et al. (2021) https://doi.org/10.1126/science.abh1282	Pokay DB	https://doi.org/10.1126/science.abh1282
H655Y	S	False	anthropozoonotic_events	 Six minks were intranasally infected with WA1 isolate, all developed this mutation during infection.  Esclera et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1
R682W	S	False	anthropozoonotic_events	 Six minks were intranasally infected with WA1 isolate, three developed this furin clevage site mutation during infection,  But cleavage site loss during subsequent Vero cell culture is a known phenomenon, therefore this may be artifactual.  Esclera et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1
T259K	S	False	anthropozoonotic_events	 Six minks were intranasally infected with WA1 isolate, three developed this mutation during infection.  Esclera et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.05.455290v1
ins215KLRS, N501Y, H655Y	S	False	anthropozoonotic_events	 Mouse-adapted SARS-CoV-2 mutations after 11 serial passages in various immunocompromised mice strains.  Rathnasinghe et al. (2021) https://dx.doi.org/10.1101%2F2021.01.19.21249592	Pokay DB	https://dx.doi.org/10.1101%2F2021.01.19.21249592
N501T, G142D	S	False	anthropozoonotic_events	 These variants dominate in mink infections in North America, sometime supplemented with F486L.    The Y453F variant found in other jurisdictions in mink infections is notably absent in North America.  Cai and Cai (2021) https://www.medrxiv.org/content/10.1101/2021.03.18.21253734v3	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.03.18.21253734v3
Y505H	S	False	anthropozoonotic_events	 Observed first in a single tiger (cohort of 5), potential adaptation.  McAloose et al. (2020) https://dx.doi.org/10.1128/mBio.02220-20	Pokay DB	https://dx.doi.org/10.1128/mBio.02220-20
G496D	S	False	anthropozoonotic_events	 Observed first in three tigers (cohort of 5), potential adaptation.  McAloose et al. (2020) https://dx.doi.org/10.1128/mBio.02220-20	Pokay DB	https://dx.doi.org/10.1128/mBio.02220-20
F456Y	S	False	anthropozoonotic_events	 Observed first in a single tiger (cohort of 5), potential adaptation.  McAloose et al. (2020) https://dx.doi.org/10.1128/mBio.02220-20	Pokay DB	https://dx.doi.org/10.1128/mBio.02220-20
T716I	S	False	anthropozoonotic_events	 Observed first in a single tiger (cohort of 5), potential adaptation.  McAloose et al. (2020) https://dx.doi.org/10.1128/mBio.02220-20	Pokay DB	https://dx.doi.org/10.1128/mBio.02220-20
Q493K, Q498Y, P499T 	S	False	anthropozoonotic_events	" Combo observed first in a mouse-adapted SARS-CoV-2 strain (MA10).  Leist	et al. (2020) https://dx.doi.org/10.1016%2Fj.cell.2020.09.050"	Pokay DB	https://dx.doi.org/10.1016%2Fj.cell.2020.09.050
G270D, Y462F, F495L	S	False	anthropozoonotic_events	 Observed in first of two Netherlands mink cohorts, potential adaptation.   Oreshkova et al. (2020) http://dx.doi.org/10.2807/1560-7917.ES.2020.25.23.2001005	Pokay DB	http://dx.doi.org/10.2807/1560-7917.ES.2020.25.23.2001005
N501T, D634G	S	False	anthropozoonotic_events	 Observed in second of two Netherlands mink cohorts, potential adaptation.    Oreshkova et al. (2020) http://dx.doi.org/10.2807/1560-7917.ES.2020.25.23.2001005	Pokay DB	http://dx.doi.org/10.2807/1560-7917.ES.2020.25.23.2001005
N501T	S	False	anthropozoonotic_events	 Observed in 4 separate mink farms in Denmark, but not humans, potential adaptation (diff set of farms than F486L).  Oude Munnink et al. (2020) http://dx.doi.org/10.1126/science.abe5901	Pokay DB	http://dx.doi.org/10.1126/science.abe5901
F486L 	S	False	anthropozoonotic_events	 Observed in 4 separate mink farms in Denmark, but not humans, potential adaptation (diff set of farms than N501T).  Oude Munnink et al. (2020) http://dx.doi.org/10.1126/science.abe5901	Pokay DB	http://dx.doi.org/10.1126/science.abe5901
V367F	S	False	anthropozoonotic_events	 Widespread amongst mink and humans on one farm, one mink on another farm, potential adaptation.  Oude Munnink et al. (2020) http://dx.doi.org/10.1126/science.abe5901	Pokay DB	http://dx.doi.org/10.1126/science.abe5901
G261D	S	False	anthropozoonotic_events	 Multiple mink but no humans on one farm in Denmark, potential adaptation.  Oude Munnink et al. (2020) http://dx.doi.org/10.1126/science.abe5901	Pokay DB	http://dx.doi.org/10.1126/science.abe5901
L177I	S	False	anthropozoonotic_events	 Observed in 2 separate mink farms in Denmark, but not humans, potential adaptation.  Oude Munnink et al. (2020) http://dx.doi.org/10.1126/science.abe5901	Pokay DB	http://dx.doi.org/10.1126/science.abe5901
Y453F	S	False	anthropozoonotic_events	 Observed in 4 separate mink farms in Denmark, and Y453F is circulating relatively widely in humans.  Oude Munnink et al. (2020) http://dx.doi.org/10.1126/science.abe5901  Welkers et al. (2020) https://academic.oup.com/ve/advance-article/doi/10.1093/ve/veaa094/6025194	Pokay DB	"http://dx.doi.org/10.1126/science.abe5901;https://academic.oup.com/ve/advance-article/doi/10.1093/ve/veaa094/6025194"
N501T, S686G	S	False	anthropozoonotic_events	 Emergent variants observed in tandem in ferrets post-serial infection.  Richard et al. (2020) https://doi.org/10.1038/s41467-020-17367-2	Pokay DB	https://doi.org/10.1038/s41467-020-17367-2
E484A, Y505H, S477N, N501Y	S	False	antibody_epitope_effects	 Using molecular dynamics simulation, ACE2-RBD (Omicron) complex is destabilized by the E484A and Y505H mutations and stabilized by S477N and N501Y mutations.  Zhang et al. (2022) https://outbreak.info/resources/2022.06.05.493249	Pokay DB	https://outbreak.info/resources/2022.06.05.493249
E484K, N501Y	S	False	antibody_epitope_effects	 Trimeric proteins FSR16m had a 0.025x fold change in IC50 in B.1.1.529 Omicron  Chonira et al. (2022) https://www.biorxiv.org/content/10.1101/2022.05.30.493765v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2022.05.30.493765v1
E484K, N501Y	S	False	antibody_epitope_effects	 Trimeric proteins FSR22 had a 0.0015x fold change in IC50 in B.1.1.529 Omicron  Chonira et al. (2022) https://www.biorxiv.org/content/10.1101/2022.05.30.493765v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2022.05.30.493765v1
Q677P	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Broad USA variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
l692V	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
N501T	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
Y453F	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
H69del, V70del	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Cluster 5/Mink variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
K1191N	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Florida variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
Q493K	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Florida variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
N439K	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
H69del, V70del	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.258 variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
L452R	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Epsilon (B.1.427/429) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
W152C	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Epsilon (B.1.427/429) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
S13I	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Epsilon (B.1.427/429) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
L452R	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.526.1 [B.1.637] variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
Y144del	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.526.1 [B.1.637] variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
D80G	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.526.1 [B.1.637] variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
A701V	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in lota (B.1.526) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
E484K	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in lota (B.1.526) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
S477N	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in lota (B.1.526) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
D253G	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in lota (B.1.526) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
T95l	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in lota (B.1.526) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
L5F	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in lota (B.1.526) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
Q677H	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
E484K	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
Y144del	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
H69del, V70del	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Eta (B.1.525) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
E484K	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Zeta (P.2) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
A701V	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
Q677P	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
Q677H	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
K417T	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
K417N	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
L18F	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Zeta (P.2) from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
N501Y	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Gamma (P.1) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
E484K	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Gamma (P.1) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
K417T	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Gamma (P.1) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
L18F	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Gamma (P.1) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
A701V	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
N501Y	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
E484K	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
K417N	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
L242del, A243del, L244del	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
D215G	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
D80A	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
L18F	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Beta (B.1.351) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
T716	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
S892A	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
P681H	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
A570D	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
N501Y	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
Y144del	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
H69del, V70del	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Alpha (B.1.1.7) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
P681R	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Delta (B.1.617.2+AY.x) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
T478K	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Delta (B.1.617.2+AY.x) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
L452R	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Delta (B.1.617.2+AY.x) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
T19R	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Delta (B.1.617.2+AY.x) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
P681R	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.617 [India] variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
E484Q	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.617 [India] variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
L452R	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in B.1.617 [India] variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
P681H	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
T478K	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
S477N	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
K417N	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
T95I	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel polymorphism is detected in Omicron (B.1.1.529 [BA.1]) variant from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
L452R	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Omicron (B.1.1.529 [BA.1]) from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
L18F	S	False	antibody_epitope_effects	 Using the Agena MassARRAYÂ® SARS-CoV-2 Variant Panel this viral variant contributes to variant algorithm Omicron (B.1.1.529 [BA.1]) from 391 RNA specimens.  Hernandez et al. (2022) https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2022.05.28.22275691v1
E484, N501Y	S	False	antibody_epitope_effects	 Utilizing shark derived vnarbodies, S375F mutation on Omicron RBD disrupts the structure of Î²-strand, which inhibits binding with 20G6. 20G6 binds to a hidden   epitope on RBD which is highly conserved in sarbecoviruses.  Feng et al. (2022) https://onlinelibrary.wiley.com/doi/epdf/10.1002/smtd.202200387	Pokay DB	https://onlinelibrary.wiley.com/doi/epdf/10.1002/smtd.202200387
K417R	S	False	antibody_epitope_effects	 8.3 fold drop in IC50 of P22A-1D1.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417A	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P22A-1D1.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417E	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P22A-1D1.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417N	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P22A-1D1.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417T	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P22A-1D1.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417R	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P5A-1D2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417A	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P5A-1D2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417E	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P5A-1D2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417N	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P5A-1D2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417T	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P5A-1D2.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417R	S	False	antibody_epitope_effects	 1.9 fold drop in IC50 of P5A-3C8.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417A	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P5A-3C8.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417E	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P5A-3C8.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417N	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P5A-3C8.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417T	S	False	antibody_epitope_effects	 No detectable fold drop in IC50 of P5A-3C8.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417R	S	False	antibody_epitope_effects	 2.2 fold increase in IC50 of P2C-1F11.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417A	S	False	antibody_epitope_effects	 2.3 fold increase in IC50 of P2C-1F11.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417E	S	False	antibody_epitope_effects	 1.3 fold drop in IC50 of P2C-1F11.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417N	S	False	antibody_epitope_effects	 1.1 fold drop in IC50 of P2C-1F11.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
K417T	S	False	antibody_epitope_effects	 2.6 fold increase in IC50 of P2C-1F11.  Zhang et al. (2021) https://doi.org/10.1038/s41467-021-24514-w	Pokay DB	https://doi.org/10.1038/s41467-021-24514-w
F490S	S	False	antibody_epitope_effects	 Highly resistant to mAb SARS2-32 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
T345A, L517R	S	False	antibody_epitope_effects	 Highly resistant to mAb 2H04 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
S477N, S514F	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-07 and SARS2-16 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
S494P	S	False	antibody_epitope_effects	 Highly resistant to mAb SARS2-01 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
P499L	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-07, SARS2-16 and SARS2-19 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
F486Y	S	False	antibody_epitope_effects	 Highly resistant to mAbs 1B07 and SARS2-16 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
F486S	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-07, SARS2-19, 1B07, SARS2-16 and 2B04 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
T478I	S	False	antibody_epitope_effects	 Highly resistant to mAb SARS2-16 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484A	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-01, 1B07, SARS2-32, SARS2-35 and SARS2-07 of 10 antibodies tested, and moderately high resistance to the remaining.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484D	S	False	antibody_epitope_effects	 Highly resistant to mAb 1B07 of 10 antibodies tested, and moderately high resistance to the remaining.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484G	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-01, 1B07, SARS2-32, SARS2-35 and 2B04 of 10 antibodies tested, and moderately high resistance to the remaining.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484K	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-01, SARS2-02, 1B07, SARS2-16, SARS2-32, SARS2-35 and 2B04 of 10 antibodies tested, and moderately high resistance to the remaining.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
T345A	S	False	antibody_epitope_effects	 Highly resistant to mAbs 2H04 and SARS2-01 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
T345N	S	False	antibody_epitope_effects	 Highly resistant to mAb 2H04 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
T345S	S	False	antibody_epitope_effects	 Highly resistant to mAb 2H04 of 10 antibodies tested, with moderate resistance to many of the remaining.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
R346G	S	False	antibody_epitope_effects	 Highly resistant to mAb SARS2-01 and moderately resistant to 2H04 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
K444E	S	False	antibody_epitope_effects	 Highly resistant to mAb SARS2-35 of 10 antibodies tested, with moderate resistance to many of the remaining..  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
K444N 	S	False	antibody_epitope_effects	 Highly resistant to mAb SARS2-01 and moderately resistant to 2H04 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
G446D	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-02, SARS2-32 and SARS2-35 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
G446V	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-01, SARS2-02, SARS2-32 and SARS2-35 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
N450D	S	False	antibody_epitope_effects	 Highly resistant to mAb SARS2-07 nd moderately resistant to SARS2-16 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
N450K	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-01 and SARS2-32 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
N450Y	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-01 and SARS2-32 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
L452R	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-01, SARS2-02 and SARS2-32 of 10 antibodies tested.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
S477G	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-07, SARS2-16 and SARS2-19 of 10 antibodies tested, and moderately high resistance to the remaining.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
S477N	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-01, SARS2-07, SARS2-16 and SARS2-19 of 10 antibodies tested, and moderately high resistance to the remaining.  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
S477R	S	False	antibody_epitope_effects	 Highly resistant to mAbs SARS2-07, SARS2-16 and SARS2-19 of 10 antibodies tested  Liu et al. (2020) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
S494F 	S	False	antibody_epitope_effects	 For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ~2.5x drop of neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
F490S 	S	False	antibody_epitope_effects	 For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
C480S	S	False	antibody_epitope_effects	 For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
C480R	S	False	antibody_epitope_effects	 For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
E484K	S	False	antibody_epitope_effects	 For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
E484G	S	False	antibody_epitope_effects	 For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
E484D	S	False	antibody_epitope_effects	 For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
C488Y	S	False	antibody_epitope_effects	 For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
C488S	S	False	antibody_epitope_effects	 For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
F490S	S	False	antibody_epitope_effects	 For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
F490L	S	False	antibody_epitope_effects	 For highly potent RBD-binding neutralizing antibody ADI-56443 this mutation causes ablation of neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
F490I	S	False	antibody_epitope_effects	 For NTD-binding neutralizing antibody ADI-56479 this mutation causes a 1000x drop in neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
F490C	S	False	antibody_epitope_effects	 For NTD-binding neutralizing antibody ADI-56479 this mutation causes a 1000x drop in neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
W152R	S	False	antibody_epitope_effects	 For NTD-binding neutralizing antibody ADI-56479 this mutation causes a 1000x drop in neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1 	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
E484K	S	False	antibody_epitope_effects	 Multiple individuals in two related households were infected with a newly acquired E484K mutation within the B.1.311 lineage.   The timing and patterns of subsequent spread were consistent   with de novo emergence of this E484K variant in the initially affected individual who had been treated with bamlanivimab monotherapy.   The subsequent transmission to close contacts occurred several days after the resolution of symptoms and the end of this patient's quarantine period.  Sabin et al. (2021) https://www.medrxiv.org/content/10.1101/2021.10.02.21264415v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.10.02.21264415v1
N440D, Y489H, Q493K, N501Y	S	False	antibody_epitope_effects	 Pseudotype for Day 146 virus from a chronically infected patient: resistant to neutralization by mAb C1A-B12, and   was still resistant to the affinity enhanced antibodies derived from it (i.e. no affinity maturation effect on neutralization).  Clark et al. (2021) https://dx.doi.org/10.1016%2Fj.cell.2021.03.027	Pokay DB	https://dx.doi.org/10.1016%2Fj.cell.2021.03.027
E484A, F486I, Y489H, N501Y	S	False	antibody_epitope_effects	" Pseudotype for Day 152 virus from a chronically infected patient: although mAb C1A-B12 had no activity against this pseudotype,   all three affinity optimized versions were active; the antibody containing the most mutations,   C1A-B12.3, was the most potent (IC50 <0.5 Î¼g/mL).  Clark et al. (2021) https://dx.doi.org/10.1016%2Fj.cell.2021.03.027"	Pokay DB	https://dx.doi.org/10.1016%2Fj.cell.2021.03.027
L18F, T20N, P26S, D138Y, R190S	S	False	antibody_epitope_effects	" The neutralization titer of NTD-binding mAb159 was 133-fold reduced on P.1 compared to Victoria (~wild type), with only 64% neutralization at 10 Î¼g/mL.   Residues 20, 18, and 138 form a cluster underlying the 245â€“259 loop, which inserts into a groove between the light and heavy chains of Fab 159. In addition,  the N-terminal residues preceding residue 18 interact with the antibody and may be perturbed.   Given that there is likely a single supersite (""i"") for potent NTD-binding antibodies, the binding of many of these are likely affected.  Using 20 potent (primaruly anti-RBD) antibodies, neutralization was measured by a focus reduction neutralization test (FRNT) and compared with   neutralization of Victoria (~wild type) and variants B.1.1.7 and B.1.351. Compared to Victoria neutralization by the mAbs was significantly impacted by P.1,   with 12/20 showing > 10-fold reduction in FRNT50 titer and a number showing complete knockout of activity. The results with P.1 showed a   greater impact compared to B.1.1.7 but were, as expected, similar to those with B.1.351.  Dejnirattisai et al. (2021) https://doi.org/10.1016/j.cell.2021.03.055"	Pokay DB	https://doi.org/10.1016/j.cell.2021.03.055
E406W	S	False	antibody_epitope_effects	 >90% drop in antibody binding (ELISA) by this variant against mAbs VH-Fc and IgG1 ab1.  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
K417N	S	False	antibody_epitope_effects	 >20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
K444N	S	False	antibody_epitope_effects	 ~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
L452R	S	False	antibody_epitope_effects	 ~20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against monoclonal antibody VH ab6.  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
E484K	S	False	antibody_epitope_effects	 Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
E484Q	S	False	antibody_epitope_effects	 >20% (ELISA significance threshold) drop in antibody binding by this variant against monoclonal antibody VH-Fc ab8.  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
E484D	S	False	antibody_epitope_effects	 Nearly complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8.  >20% (ELISA significance threshold) drop in antibody binding by this variant against IgG1 monoclonal antibody ab1.  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
F486S	S	False	antibody_epitope_effects	 >60% drop in antibody binding (ELISA) by this variant against monoclonal antibody VH-Fc ab8.  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
N487R	S	False	antibody_epitope_effects	 >20% (ELISA significance threshold) drop in antibody binding by this variant against IgG1 monoclonal antibody ab1.  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
F490L	S	False	antibody_epitope_effects	 Complete loss of binding in ELISA by the variant against monoclonal antibody ab8  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
F490S	S	False	antibody_epitope_effects	 Complete loss of binding in ELISA by the variant against monoclonal antibody ab8  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
K417N, E484K, N501Y	S	False	antibody_epitope_effects	 Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1.  Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike   protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM).  Complete loss of neutralization by these two antibodies was also observed.  Sun et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1
L452R	S	False	antibody_epitope_effects	 10 of 14 RBD-specific mAbs that showed at least 10-fold reduced neutralization of B.1.427/B.1.429 variant pseudotype (S13I, W152C, and L452R) were also found  to poorly bind to just a L452R RBD mutant, demonstrating a role for this mutation as an escape  mechanism for certain RBD-targeting mAbs.  McCallum et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1
S13I, W152C, L452R	S	False	antibody_epitope_effects	 14 of 34 RBD-specific mAbs showed reduced neutralization to the B.1.427/B.1.429 variant pseudotype.  McCallum et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1
S13I	S	False	antibody_epitope_effects	 The S13I mutation dampened binding of 5 mAbs and abrogated binding of 5 additional mAbs out of 11 neutralizing mAbs evaluated.  Predicted to shift the signal peptide cleavage site from S13-Q14 to C15-V16, which can affect NTD conformation.   PG: in saying S12F does not shift the signal peptide nor affect mAb binding, this manuscript appears to contradict the   text of McCallum et al.'s earlier 2021 manuscript stating that S12F *does* affected some mAb binding  via putative signal peptide shift.  McCallum et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1
W152C	S	False	antibody_epitope_effects	 The W152C mutation reduced recognition of six NTD neutralizing mAbs, including a complete loss of binding for two of them, with a complementary  pattern to that observed for S13I (also found in lineage B.1.427/B.1.429) out of 11 neutralizing mAbs evaluated.  McCallum et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1
S13I, W152C	S	False	antibody_epitope_effects	 The B.1.427/B.1.429 S13I/W152C NTD did not bind to any NTD-directed neutralizing mAbs, which are known to  target a single antigenic site (antigenic site i), whereas binding of the non-neutralizing  S2L20 mAb to the NTD antigenic site iv was not affected by any mutants, confirming proper  retention of folding.  McCallum et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1
N501Y	S	False	antibody_epitope_effects	 Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may  have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that  the individual N501Y mutation does not contribute to altered viral properties by itself, but  may contribute to a collective conformational shift produced by multiple mutations.  Klegerman et al. (2021) https://doi.org/10.1101/2021.04.26.441517	Pokay DB	https://doi.org/10.1101/2021.04.26.441517
N501Y	S	False	antibody_epitope_effects	 Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.  Collier et al. (2021) https://doi.org/10.1038/s41586-021-03412-7	Pokay DB	https://doi.org/10.1038/s41586-021-03412-7
E484K	S	False	antibody_epitope_effects	 Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.  Collier et al. (2021) https://doi.org/10.1038/s41586-021-03412-7	Pokay DB	https://doi.org/10.1038/s41586-021-03412-7
E484K	S	False	antibody_epitope_effects	 Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.  Li et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1
K417N, E484K, N501Y	S	False	antibody_epitope_effects	 Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.  Hu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1
P384A	S	False	antibody_epitope_effects	" Resulted in complete loss of neutralization by mAb COVA1-16, a cluster III RBD-specific mAb	  that allosterically competes with ACE2 rather than directly blocking the binding site.  Rees-Spear et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1"	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1
K417V	S	False	antibody_epitope_effects	 Less susceptible to COVA2-07 mediated neutralization, and neutralization by COVA2-04 (which uses the VH3-53 gene) is abolished.  Rees-Spear et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1
L452K	S	False	antibody_epitope_effects	 Renders pseudotyped virus resistant to neutralization by the cluster I mAb COVA2-29.  Rees-Spear et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1
S494D	S	False	antibody_epitope_effects	 Destroys neutralization activity by both COVA2-29 (cluster I) and COVA1-12 (cluster VI).  Rees-Spear et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1
T470N, E471V, I472P	S	False	antibody_epitope_effects	 This mutation prevents neutralization by COVA2-29 (cluster I), COVA2-07 (cluster III) and COVA2-02 (cluster  VII).    It also reduces the activity of the most potent mAb COVA1-18 (cluster I) by 3-fold, whereas this   mAb is only minimally affected by other mutations. Moreover, TEI470-2NVP lowers the potency   of the structurally unmapped non-RBD cluster XI mAb,  COVA1-21, to the limit of detection.  Thus, this mutation negatively impacts the most mAbs, including representatives from four   separate epitope clusters.  Rees-Spear et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1
L455Y, F456L	S	False	antibody_epitope_effects	 This double substitution reduces neutralization by RBD-specific mAbs from different clusters,    specifically, the cluster I mAb COVA2-29, cluster III mAb COVA2-07 and cluster VI mAb COVA1-12.   For COVA1-12 all neutralization activity is abolished, while COVA2-07 activity is                     just below the level required to calculate an IC50 value.  Rees-Spear et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1
K444T, V445S, G446T	S	False	antibody_epitope_effects	 Results in 3.7-fold drop in neutralization potency for COVA2-29, which is a cluster I RBD141 specific antibody.  Rees-Spear et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1
D80A	S	False	antibody_epitope_effects	 Abolishes neutralizing activity of N-terminal-domain-directed mAb 4-19.  Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2	Pokay DB	https://doi.org/10.1038/s41586-021-03398-2
Y453F	S	False	antibody_epitope_effects	 10-fold reduction in binding efficiency vs wild type for MAb REGN10933.  Rappazzo et al. (2021) https://doi.org/10.1126/science.abf4830	Pokay DB	https://doi.org/10.1126/science.abf4830
R346S	S	False	antibody_epitope_effects	 Resistent to class 2/3 antibody C603.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2  Clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)   show pronounced increase in binding to the variant.   Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2"
T345A	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb 2H04 and SARS2-01.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
T345N	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb 2H04.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
T345S	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb 2H04, and   slight resistence to a broad range of other antibodies.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
R346G	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-01,   mild resistence to 2H04.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2  Clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)   show pronounced increase in binding to the variant.   Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2	Pokay DB	"https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2"
A352D	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-01.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
L441R	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb 2H04.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
K444E	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
K444N	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2  Abolishes binding efficiency vs wild type for mAb REGN10933.  Rappazzo et al. (2021) https://doi.org/10.1126/science.abf4830	Pokay DB	"https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;https://doi.org/10.1126/science.abf4830"
G446D	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
G446V	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2  Massive reduction in binding efficiency vs wild type for mAb REGN10933.  Rappazzo et al. (2021) https://doi.org/10.1126/science.abf4830	Pokay DB	"https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;https://doi.org/10.1126/science.abf4830"
N450K	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
N450Y	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
N450D	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
L452R	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
S477N	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows some resistence across all antibodies tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
S477G	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows some resistence across all antibodies tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
S477R	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
T478I	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to more than one antibody.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
K417N, E484K, N501Y	S	False	antibody_epitope_effects	" Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background   Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background   Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background  Wibmer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1  Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.  Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w "	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;https://doi.org/10.1038/s41591-021-01294-w"
E484K, N501Y	S	False	antibody_epitope_effects	 Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.  Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.  Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w 	Pokay DB	https://doi.org/10.1038/s41591-021-01294-w
K417N	S	False	antibody_epitope_effects	 5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs)  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2  Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD).  Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.  Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;https://doi.org/10.1038/s41586-021-03398-2"
E484K	S	False	antibody_epitope_effects	 Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,   but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)   show pronounced increase in binding to the variant.   Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2  Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,   and broad low level resistence against much of the rest of the panel.  Liu et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2  Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold   or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2  Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.  Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w  Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121.  Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)  Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2  Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.  Rappazzo et al. (2021) https://doi.org/10.1126/science.abf4830	Pokay DB	"https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;https://doi.org/10.1038/s41591-021-01294-w;https://doi.org/10.1038/s41586-021-03398-2;https://doi.org/10.1126/science.abf4830"
E484A	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,   and broad low level resistence against much of the rest of the panel.  Liu et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
E484D	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb 1B07.  Liu et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2  Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.  Rappazzo et al. (2021) https://doi.org/10.1126/science.abf4830	Pokay DB	"https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;https://doi.org/10.1126/science.abf4830"
F486S	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 5 antibodies.  Liu et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
F486Y	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb 1B07.  Liu et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
F490S	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-32.  Liu et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
S494P	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows resistence to mAb SARS2-01.  Liu et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2  Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.  Rappazzo et al. (2021) https://doi.org/10.1126/science.abf4830	Pokay DB	"https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;https://doi.org/10.1126/science.abf4830"
P499L	S	False	antibody_epitope_effects	 Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 3 antibodies.  Liu et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
S477N, S514F	S	False	antibody_epitope_effects	 While S477N itself is highly resistent to a broad range of monoclonal antibodies, combined with S514F high neutralization  is restricted to only three antibodies in a broad screen.  Liu et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
T345A, L517R	S	False	antibody_epitope_effects	 The combination has only a mild effect of making neutralizing mAbs less effective vs. T345A alone.  Liu et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
L242del	S	False	antibody_epitope_effects	" Ablates binding of Spike N terminal domain targeting monoclonal antibody 4A8, by disruption of N5-loop/supersite loop, may work synergistically with   501Y.V2 (""South African"") lineage background variant R246I to disrupt paratope binding. [PG: del extent simplified to accomodate minor position realignments]  Wibmer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1  B.1.351 pseudotyped virus model ablates neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, 4A8, 2-17, and 4-19 (independent of S:p.R246I).  Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2"	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;https://doi.org/10.1038/s41586-021-03398-2"
R246I	S	False	antibody_epitope_effects	" Ablates binding of Spike N terminal domain targeting monoconal anibody 4A8, this residue is known to be key for CDR-H1 mediated  interactions. May work synergistically with 501Y.V2 (""South African"") lineage background deletion 242del,243del,244del to disrupt paratope binding  via steric clash with residue R102.  Wibmer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1  B.1.351 pseudotyped virus model ablates neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, 4A8, and 4-19 (independent of S:pL242_L244del).  Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2"	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;https://doi.org/10.1038/s41586-021-03398-2"
N234Q	S	False	antibody_epitope_effects	 Markedly resistant to neutralizing antibodies, unlike most ablated N-glycosylation sites.  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
L452R	S	False	antibody_epitope_effects	 Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
V483A	S	False	antibody_epitope_effects	 Resistent to some neutralizing antibodies: mAbs X593 and P2B-2F6  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012  Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant.  Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2	Pokay DB	"https://doi.org/10.1016/j.cell.2020.07.012;https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2"
F490L	S	False	antibody_epitope_effects	 Resistent to some neutralizing antibodies: mAbs X593, 261-262, H4, and P2B-2F6  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
A475V	S	False	antibody_epitope_effects	 Resistent to some neutralizing antibodies: mAbs 157, 247, CB6, P2C-1F11, B38, and CA1  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012  Resistent to some class 1 (Spike 'up' conformation) antibodies tested.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"https://doi.org/10.1016/j.cell.2020.07.012;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
N439K	S	False	antibody_epitope_effects	 Resistent to neutralizing mAb H00S022  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012  6.8% of 442 tested post-infection sera showed a greater than two-fold  reduction in binding to N439K RBD as compared to WT. In some individuals, the >two-fold reduction diminished the RBD ED50 response below 30  a threshold previously determined to be a cutoff for specific binding  Thomson et al. (2021) https://doi.org/10.1016/j.cell.2021.01.037  Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,   but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)   show pronounced increase in binding to the variant.   Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2  Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"https://doi.org/10.1016/j.cell.2020.07.012;https://doi.org/10.1016/j.cell.2021.01.037;https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
N440K	S	False	antibody_epitope_effects	 Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,   but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)   show pronounced increase in binding to the variant.   Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2  Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2  Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555.  Abolishes binding of mAb ADG-1.  Rappazzo et al. (2021) https://doi.org/10.1126/science.abf4830  N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23  Cheng et al. (2021) https://doi.org/10.1186/s12985-021-01554-8	Pokay DB	"https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;https://doi.org/10.1126/science.abf4830;https://doi.org/10.1186/s12985-021-01554-8"
S477N	S	False	antibody_epitope_effects	 Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,   but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)   show pronounced increase in binding to the variant.   Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2
V367F	S	False	antibody_epitope_effects	 Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,   but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)   show pronounced increase in binding to the variant.   Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2
A475V	S	False	antibody_epitope_effects	 Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,   but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)   show pronounced increase in binding to the variant.   Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2
Q493R	S	False	antibody_epitope_effects	 Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,   but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)   show pronounced increase in binding to the variant.   Gaebler et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2  Somewhat resistent to some class 1 (Spike 'up') antibodies tested.  Mix of non- to strongly resistent in class 2 antibodies tested.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2  Massive reduction in binding efficiency vs wild type for mAbs CB6/LY-CoV16 and LY-CoV555.  Rappazzo et al. (2021) https://doi.org/10.1126/science.abf4830	Pokay DB	"https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;https://doi.org/10.1126/science.abf4830"
Y508H	S	False	antibody_epitope_effects	 Resistent to neutralizing mAb H014  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
A831V	S	False	antibody_epitope_effects	 Resistent to neutralizing mAb B38  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
I472V	S	False	antibody_epitope_effects	 Resistent to neutralizing mAb X593 (on D614G background)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
A435S	S	False	antibody_epitope_effects	 Resistent to neutralizing mAb H014 (on D614G background)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
N165Q	S	False	antibody_epitope_effects	 Increased sensitivity to neutralizing antibodies.  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
N331X	S	False	antibody_epitope_effects	 Ablation of N-glycosylation site in RBD drastically reduces infectivity.  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
I332P	S	False	antibody_epitope_effects	 Ablation of N-glycosylation site in RBD drastically reduces infectivity (proline disallowed in N-X-S/T glycosylation pattern).  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
N343X	S	False	antibody_epitope_effects	 Ablation of N-glycosylation site in RBD drastically reduces infectivity.  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
I344P	S	False	antibody_epitope_effects	 Ablation of N-glycosylation site in RBD drastically reduces infectivity (proline disallowed in N-X-S/T glycosylation pattern).  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
S12P	S	False	antibody_epitope_effects	 Alters cleavage to occur between residues C15 and V16, thereby eliminating the C15-C136 disulfide bond â€“ similarly to escape mutants at positions C15 and C136.  This in turn decreases to varying degrees N terminal domain antigen recognition by supersite i mAbs S2L28, S2M28, S2X28, S2X333, 4A8.  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
S12F	S	False	antibody_epitope_effects	 A variant in low % circulation, predicted to have a similar effect to the experimentally verified S12P, which introduces a new signal peptide, altering  cleavage to occur between residues C15 and V16, thereby eliminating the C15-C136 disulfide bond â€“ similarly to escape mutants at positions C15 and C136.  This in turn decreases to varying degrees N terminal domain antigen recognition by supersite i mAbs S2L28, S2M28, S2X28, S2X333, 4A8.  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
L18F	S	False	antibody_epitope_effects	" Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475  Ablates neutralization by N-terminal-domain-targeting mAbs 4-19.  Impairs neutralization by N-terminal-domain-targeting mAbs 4A8 and 2-17.  Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2"	Pokay DB	"https://doi.org/10.1101/2021.01.14.426475;https://doi.org/10.1038/s41586-021-03398-2"
C136Y	S	False	antibody_epitope_effects	 Massively decreases N terminal domain antigen recognition by supersite i mAbs S2L28, S2M28, S2X28, S2X333, 4A8.  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
K147T	S	False	antibody_epitope_effects	 Massively decreases N terminal domain antigen recognition by supersite i mAbs S2M28, S2X28, S2X333, 4A8 (but not S2L28).  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
Y144del	S	False	antibody_epitope_effects	" Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 1% to 0.17% (poorer immune recognition)  Together with other B1.1.7 lineage mutational changes (Spike: N501Y, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.   Haynes et al. (2021) https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1  Massive reduction in S2M28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""   Massive reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""   Massive reduction in S2X333 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""   Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition)   McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475  Abolishes neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8.  Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2"	Pokay DB	"https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;https://doi.org/10.1101/2021.01.14.426475;https://doi.org/10.1038/s41586-021-03398-2"
H146Y	S	False	antibody_epitope_effects	" Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition), but much milder effect on mAbs within antigenic supersite ""i""  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475"	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
N149Q	S	False	antibody_epitope_effects	" Major reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but little effect on other mAbs within that supersite  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475"	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
A222V	S	False	antibody_epitope_effects	" Not associated with significant reduction of EC50 (recognition) in any antigenic supersite ""i"" monoclonal antibodies.  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475"	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
R246A	S	False	antibody_epitope_effects	" Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Major reduction in S2M28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Minor reduction in S2X333 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition)    McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475"	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
D253G	S	False	antibody_epitope_effects	" Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475"	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
D253Y	S	False	antibody_epitope_effects	" Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475"	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
S254F	S	False	antibody_epitope_effects	" Not associated with significant reduction of EC50 (recognition) in any antigenic supersite ""i"" monoclonal antibodies.  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475"	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
N501Y	S	False	antibody_epitope_effects	" Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition)  Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.  Haynes et al. (2021) https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1  4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2  Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.  Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w   Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)  Shen et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2  Lowered	the	neutralization potency of mAb COVA1-12 to the	limit	of the assay.  Decrease in potency	was	observed against the N501Y pseudotype	for the cluster IX mAb COVA2-17.  Rees-Spear et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1"	Pokay DB	"https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;https://doi.org/10.1038/s41591-021-01294-w;https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1"
A570D	S	False	antibody_epitope_effects	 Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant raises PIWAS epitope score from 3.6% to 6.2% (improved immune recognition)  Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.  Haynes et al. (2021) https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1
P681H	S	False	antibody_epitope_effects	 Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition)  Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.  Haynes et al. (2021) https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1  This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.  Johnson et al. (2020)  https://doi.org/10.1101%2F2020.08.26.268854   Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.  Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w 	Pokay DB	"https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;https://doi.org/10.1101%2F2020.08.26.268854;https://doi.org/10.1038/s41591-021-01294-w"
T716I	S	False	antibody_epitope_effects	 Not in a major wildtype epitope, mutant increases PIWAS epitope score from 0.69% to 2.3%  Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity.  Haynes et al. (2021) https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1
S982A	S	False	antibody_epitope_effects	 Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score  Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity.  Haynes et al. (2021) https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1
D1118H	S	False	antibody_epitope_effects	 Not in a major wildtype epitope, mutant has no significant effect on PIWAS epitope score  Found in B.1.1.7 lineage, but assumed to not pay a major role in antigenicity.  Haynes et al. (2021) https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1
W633P	S	False	antibody_epitope_effects	 Confers a significant PIWAS value decrease (reduced antigenicity)   Haynes et al. (2020) https://www.medrxiv.org/content/10.1101/2020.11.23.20235002v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2020.11.23.20235002v1
S686V	S	False	antibody_epitope_effects	 Confers a significant PIWAS value decrease (reduced antigenicity)  Haynes et al. (2020) https://www.medrxiv.org/content/10.1101/2020.11.23.20235002v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2020.11.23.20235002v1
H69del, V70del, N501Y	S	False	antibody_epitope_effects	 Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.  Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w   Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x).  PG: these effects are laregly missing in the deletion-alone data  Shen et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	Pokay DB	"https://doi.org/10.1038/s41591-021-01294-w;https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2"
H69del, V70del	S	False	antibody_epitope_effects	 Reduces neutralization by structurally unmapped mAb COVA1-21 (cluster XI).  Rees-Spear et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1
H69del, V70del	S	False	convalescent_plasma_binding	 1.33x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.   Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
Y144del	S	False	convalescent_plasma_binding	 1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.   Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
N501Y	S	False	convalescent_plasma_binding	 1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
A570D	S	False	convalescent_plasma_binding	 1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
P681H	S	False	convalescent_plasma_binding	 1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T716I	S	False	convalescent_plasma_binding	 1.58x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
S982A	S	False	convalescent_plasma_binding	 1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D1118H	S	False	convalescent_plasma_binding	 1.96x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L18F	S	False	convalescent_plasma_binding	 1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Compare to decreased binding in full Spike variant complements for major lineages  containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D80A	S	False	convalescent_plasma_binding	 2.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D215G	S	False	convalescent_plasma_binding	 2.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L242del, A243del, L244del	S	False	convalescent_plasma_binding	 1.97x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
R246I	S	False	convalescent_plasma_binding	 1.53x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
K417N	S	False	convalescent_plasma_binding	 2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
E484K	S	False	convalescent_plasma_binding	 1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
A701V	S	False	convalescent_plasma_binding	 1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T20N	S	False	convalescent_plasma_binding	 1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
P26S	S	False	convalescent_plasma_binding	 1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D138Y	S	False	convalescent_plasma_binding	 1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
R190S	S	False	convalescent_plasma_binding	 1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
K417T	S	False	convalescent_plasma_binding	 1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
H655Y	S	False	convalescent_plasma_binding	 1.48x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T1027I	S	False	convalescent_plasma_binding	 1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L5F	S	False	convalescent_plasma_binding	 No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T95I	S	False	convalescent_plasma_binding	 No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D253G	S	False	convalescent_plasma_binding	 1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L5F, T95I, D253G, E484K, A701V	S	False	convalescent_plasma_binding	 This variant combination (representing lineage B.1.526) showed a 1.02x increase in Spike binding (relative   to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
S13I	S	False	convalescent_plasma_binding	 1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
W152C	S	False	convalescent_plasma_binding	 1.15x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L452R	S	False	convalescent_plasma_binding	 2.15x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
S13I, W152C, L452R	S	False	convalescent_plasma_binding	 This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding   (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset, indicating ablated marginal effect from L452R.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
"L452R, E484Q	"	S	False	convalescent_plasma_binding	 This variant combination (representing lineage B.1.617) showed a 1.22x decrease in Spike binding (relative   to D614G alone) by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred fro common knowledge]  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
N439K	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~25-50% in the S2D97 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
N439K	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~25-50% in the S2D97 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
N439K, K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~25-50% in the S2D97 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
N439K	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~15-125% in the REGN10987 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
N439K, K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~25-50% in the S2H14 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~25-50% in the S2H14 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
N439K, K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~12-88% in the S2H7 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~12-88% in the S2H7 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
K417V 	S	False	convalescent_plasma_escape	 Increases in neutralization efficiency up to ~25% in the S2X192 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
N439K, K417V 	S	False	convalescent_plasma_escape	 Increases in neutralization efficiency up to ~25% in the S2X192 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~50% in the S2X128 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
N439K, K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~50% in the S2X128 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~75% in the S2X71 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
N439K, K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~75% in the S2X71 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~75% to increase up to ~25% in the S2D8 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
N439K, K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~75% to increase up to ~25% in the S2D8 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~60% in the REGN10933 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
N439K, K417V	S	False	convalescent_plasma_escape	 Decreases in neutralization efficiency up to ~60% in the REGN10933 antibiotic.  Thomson et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.04.355842v1
E484K	S	False	convalescent_plasma_escape	 Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484D	S	False	convalescent_plasma_escape	 Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484A	S	False	convalescent_plasma_escape	 Significant decrease in neutralization across 15 of 16 sera tested 7-17 days post symptoms onset.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
S477N	S	False	convalescent_plasma_escape	 Significant decrease in neutralization across 11 of 16 sera tested 7-17 days post symptoms onset.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
N450Y	S	False	convalescent_plasma_escape	 Significant decrease in neutralization across 4 of 16 sera tested 7-17 days post symptoms onset.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
T354S	S	False	convalescent_plasma_escape	 No effective neutralization in 1 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
L441R	S	False	convalescent_plasma_escape	 No effective neutralization in 2 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
K444E	S	False	convalescent_plasma_escape	 No effective neutralization in 3 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
G446D	S	False	convalescent_plasma_escape	 No effective neutralization in 1 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
G446V	S	False	convalescent_plasma_escape	 No effective neutralization in 3 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
N450D	S	False	convalescent_plasma_escape	 No effective neutralization in 2 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
N450Y	S	False	convalescent_plasma_escape	 No effective neutralization in 2 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
L452R	S	False	convalescent_plasma_escape	 No effective neutralization in 3 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
S477G	S	False	convalescent_plasma_escape	 No effective neutralization in 2 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
T478I	S	False	convalescent_plasma_escape	 No effective neutralization in 2 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484A	S	False	convalescent_plasma_escape	 No effective neutralization in all 4 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484D	S	False	convalescent_plasma_escape	 No effective neutralization in all 4 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484G	S	False	convalescent_plasma_escape	 No effective neutralization in all 4 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
E484K	S	False	convalescent_plasma_escape	 No effective neutralization in all 4 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
F486S	S	False	convalescent_plasma_escape	 No effective neutralization in 1 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
F490S	S	False	convalescent_plasma_escape	 No effective neutralization in 3 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
S477N, S514	S	False	convalescent_plasma_escape	 No effective neutralization in 2 out of the 4 sera tested.  Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
F486S	S	False	convalescent_plasma_escape	 IC50 relative to wildtype drops ~8x in neutralization efficiency between 7-17 days post symptoms onset.   Liu et al. (2021) https://doi.org/10.1016/j.chom.2021.01.014	Pokay DB	https://doi.org/10.1016/j.chom.2021.01.014
Y145D	S	False	convalescent_plasma_escape	 In 12 convalescent sera more than 2 weeks and less than 2 months post infection, this NTD mutation causes a ~3.5x drop in neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
K150E	S	False	convalescent_plasma_escape	 In 12 convalescent sera more than 2 weeks and less than 2 months post infection, this NTD mutation causes a ~3.5x drop in neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
W152R	S	False	convalescent_plasma_escape	 In 12 convalescent sera more than 2 weeks and less than 2 months post infection, this NTD mutation causes a ~3.5x drop in neutralization efficiency.  Haslwanter et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.10.447999v1
S13I, W152C, L452R	S	False	convalescent_plasma_escape	 Mean 2.7x reduction of NT50 value B.1.427 (Epsilon) relative to wild type in 8 sera from older convalescent patients (52-92yo) collected 1-3m post symptom onset.  Uriu et al. (2021) https://doi.org/10.1101/2021.09.06.459005	Pokay DB	https://doi.org/10.1101/2021.09.06.459005
L452R	S	False	convalescent_plasma_escape	 Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by convalescent plasma [no cohort details provided]  Wilhelm et al. (2021) https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1
S12P	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
Q14H	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
C15G	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
P25L	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
V47M	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
W64R	S	False	convalescent_plasma_escape	 Mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset, but also  in cell culture without plasma, therefore likely a replication cycle fitness rather than polyclonal iummnuity escape variant.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
F140S	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
G142E	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
V143G	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
Y145C	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
K147N	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
K147E	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
E154K	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
A243D	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
L244P	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
S247P	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
S254Y	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
Y248H	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
W258R	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
A260V	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
A260T	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
K378R	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
K444T	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
V445E	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
V445M	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
G446R	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
N450D	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
E484K	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
Q493R	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
T604I	S	False	convalescent_plasma_escape	 Mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset, but also  in cell culture without plasma, therefore likely a replication cycle fitness rather than polyclonal iummnuity escape variant.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
A623T	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
P681S	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
F792H	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
N801D	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
S813I	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
I931M	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
Q1010R	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
V1061M	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
D1118G	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
V1128A	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
P1162S	S	False	convalescent_plasma_escape	 Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.  Schmidt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1
Q493K	S	False	convalescent_plasma_escape	 Mutation from chronically infected patient predicted to introduce clash with potent mAbs C1A-VH3-53,   and verified by pseudovirus assay against the weaker mAbs in this family.  The mutation conferred decreased sensitivity to mAb B38 but had no effect on neutralization by mAb CC12.  Clark et al. (2021) https://dx.doi.org/10.1016%2Fj.cell.2021.03.027	Pokay DB	https://dx.doi.org/10.1016%2Fj.cell.2021.03.027
N440D, Y489H, Q493K, N501Y	S	False	convalescent_plasma_escape	 Pseudotype for Day 146 virus from a chronically infected patient, neutralizing activity of purified IgG   from 3 donors was mostly unaffected by the single mutations (Q493K/R or N439K), but the day 146 S pseudotype  was resistant to neutralization.  Clark et al. (2021) https://dx.doi.org/10.1016%2Fj.cell.2021.03.027	Pokay DB	https://dx.doi.org/10.1016%2Fj.cell.2021.03.027
E484A, F486I, Y489H, N501Y	S	False	convalescent_plasma_escape	 Pseudotype for Day 152 virus from a chronically infected patient, neutralizing activity of purified IgG   from 3 donors was mostly unaffected by the single mutations (Q493K/R or N439K), but the day 152 S pseudotype  was resistant to neutralization.  Clark et al. (2021) https://dx.doi.org/10.1016%2Fj.cell.2021.03.027	Pokay DB	https://dx.doi.org/10.1016%2Fj.cell.2021.03.027
L452R, E484Q	S	False	convalescent_plasma_escape	 Pseudotyped viruses for B.1.617 was 2.3-fold resistant to neutralization by convalescent sera compared to wild type - a finding that  was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay.  The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617.  [details on the convalescent patient sera collection are not abundantly clear in the preprint]  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1
E484K	S	False	convalescent_plasma_escape	 Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that  was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay.  The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.  [details on the convalescent patient sera collection are not abundantly clear in the preprint]  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1
Y453F	S	False	convalescent_plasma_escape	 VSV pseudotyped with Y453F reduced inhibition by most of the 13 potent convalescent serum/plasma samples tested, albeit with variable efficiency   (median increase of serum/plasma titer required for 50% neutralization [NT50] = 1.62x, range = 1.02x to 3.43x), indicating that this   RBD mutation may compromise SARS-CoV-2 control by preexisting neutralizing antibody responses.  Hoffman et al. (2021) https://dx.doi.org/10.1016%2Fj.celrep.2021.109017	Pokay DB	https://dx.doi.org/10.1016%2Fj.celrep.2021.109017
N501Y	S	False	convalescent_plasma_escape	 0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe   disease 21 to 63 days post-onset.   Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
N501Y, K417N, E484K	S	False	convalescent_plasma_escape	 ~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe   disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
S13I, W152C, L452R	S	False	convalescent_plasma_escape	 Loss of neutralizing activity (PsVNA50 assay) using 6 hyperimmune immunoglobulin preparations from  convalescent plasma was minimal against B.1.249 (1.7-fold). Neutralization against 10  convalescent plasma was somewhat poorer (3.1-fold).  Tang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1
E484K	S	False	convalescent_plasma_escape	 As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for   six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.  Tang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1
N501Y	S	False	convalescent_plasma_escape	 As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for   six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.  Tang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1
E484K	S	False	convalescent_plasma_escape	 The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
N501Y	S	False	convalescent_plasma_escape	 Viruses containing the point mutations  of B.1.1.7 showed that the single point mutations (Î”69-70 and N501Y) were neutralized  as efficiently as D614G across 10 convalescent sera from April 2020 infectees.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del	S	False	convalescent_plasma_escape	 Viruses containing the point mutations  of B.1.1.7 showed that the single point mutations (Î”69-70 and N501Y) were neutralized  as efficiently as D614G across 10 convalescent sera from April 2020 infectees.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, N501Y, P681H	S	False	convalescent_plasma_escape	 These key B.1.1.7 mutations as a combination neutralized slightly less well than D614G  and this was noticeable in the lack of sera with high neutralizing titer for the viruses   across 10 convalescent sera from April 2020 infectees.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
N501Y, Q677H	S	False	convalescent_plasma_escape	" Lentiviral pseudotyped with the key mutations from COH.20G/677H (""Ohio"") lineage  was neutralized similarly to D614G in 10 convalescent sera from April 2020 infectees.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1"	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, Y453F, I692V, M1229I	S	False	convalescent_plasma_escape	 Lentiviral pseudotyped with the key mutations from Mink Cluster 5  was neutralized more easily than D614G in 10 convalescent sera from April 2020 infectees.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
S477N	S	False	convalescent_plasma_escape	 Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage  was neutralized slightly less than D614G in 10 convalescent sera from April 2020 infectees.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
L5F, T95I, D253G, S477N, A701V	S	False	convalescent_plasma_escape	" Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant   change in IC50 serum dilution concentration for 6 convalescent sera.  Zhou et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1"	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1
L5F, T95I, D253G, E484K, A701V	S	False	convalescent_plasma_escape	" Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.8x reduction in   IC50 serum dilution concentration for 6 convalescent sera.  Zhou et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1"	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1
S13I, W152C, L452R	S	False	convalescent_plasma_escape	 In 9 plasma collected 15 to 28 days after early 2020 infections, neutralization reduced 4.9-fold for  B.1.427/B.1.429 compared to wildtype (D614G).  In 13 plasma collected ~1mo after B.1.1.7 infection (nursing home in Ticino, Switzerland), neutralization   reduced to undetectable levels in many plasma for B.1.427/B.1.429 pseudotyped virus, as well as WT and other VOCs.   McCallum et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1.full.pdf
H146del	S	False	convalescent_plasma_escape	 Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots.  This variant was present in 1 patient.  McCarthy et al. (2021) https://doi.org/10.1126/science.abf6950	Pokay DB	https://doi.org/10.1126/science.abf6950
Y145del	S	False	convalescent_plasma_escape	 Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots.  This variant was present in 1 patient.  McCarthy et al. (2021) https://doi.org/10.1126/science.abf6950	Pokay DB	https://doi.org/10.1126/science.abf6950
P138del, F139del, L140del, G141del, V142del, Y143del, Y144del	S	False	convalescent_plasma_escape	 Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots.  This variant was present in 1 patient.  McCarthy et al. (2021) https://doi.org/10.1126/science.abf6950	Pokay DB	https://doi.org/10.1126/science.abf6950
L140del, G141del, V142del, Y143del	S	False	convalescent_plasma_escape	 Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots.  This variant was present in 4 patients.  McCarthy et al. (2021) https://doi.org/10.1126/science.abf6950	Pokay DB	https://doi.org/10.1126/science.abf6950
L140F, G141del, V142del, Y143del	S	False	convalescent_plasma_escape	 Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots.  This variant was present in 1 patient.  McCarthy et al. (2021) https://doi.org/10.1126/science.abf6950	Pokay DB	https://doi.org/10.1126/science.abf6950
Y144del	S	False	convalescent_plasma_escape	 Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots.  This variant was present in 4 patients.  McCarthy et al. (2021) https://doi.org/10.1126/science.abf6950	Pokay DB	https://doi.org/10.1126/science.abf6950
L244F, H245del, R246del, S247del, Y248del	S	False	convalescent_plasma_escape	 Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots.  This variant was present in 1 patient.  McCarthy et al. (2021) https://doi.org/10.1126/science.abf6950	Pokay DB	https://doi.org/10.1126/science.abf6950
L242del	S	False	convalescent_plasma_escape	 Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots.  This variant was present in 1 patient.  McCarthy et al. (2021) https://doi.org/10.1126/science.abf6950	Pokay DB	https://doi.org/10.1126/science.abf6950
F456A	S	False	convalescent_plasma_escape	 Highly ranked escape variant in most of the early and late convalescent sera in a study of 11 post-infection subjects.  Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003	Pokay DB	https://doi.org/10.1016/j.chom.2021.02.003
F456T	S	False	convalescent_plasma_escape	 Highly ranked escape variant in most of the early and late convalescent sera in a study of 11 post-infection subjects.  Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003	Pokay DB	https://doi.org/10.1016/j.chom.2021.02.003
E484P	S	False	convalescent_plasma_escape	 In 3 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,   E484P shows a resistent profile, but was mostly reduce or eliminated by    later time points (i.e. generally less resistant to immune cell somatic mutation evolution than E484Q of E484K), see Figure 5a,b.  Subject C 32 days post-infection showed >>10 fold reduction in neutralization, reducing to ~10-fold by day 104.  Subject B 26 days post-infection showed ~10 fold reduction in neutralization, but little immune escape at day 113.  Subject G 18 days post-infection showed ~7 fold reduction in neutralization, but no immune escape at day 94.  Notably, Subject G had no E484K/Q effect at either the early or late timepoints.  Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003	Pokay DB	https://doi.org/10.1016/j.chom.2021.02.003
E484Q	S	False	convalescent_plasma_escape	 In 3 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,   E484Q shows a notably resistant profile, comparable to or even more resistant than E484K at   later time points (i.e. more resistant to immune cell somatic mutation evolution), see Figure 5a,b.  Subject C 32 days post-infection showed >>10 fold reduction in neutralization, reducing to ~10-fold by day 104.  Subject B 26 days post-infection showed ~10 fold reduction in neutralization, reducing to ~4x at day 113.  Notably, Subject B also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 32,   and no E484K immune escape at day 104.  Subject I 26 days post-infection showed ~10 fold reduction in neutralization, with no reduction in escape at day 102.  Notably, Subject I also showed smaller than typical (~10 vs 30+ fold) reduction in one-month neutralization by E484K at day 26,   and no E484K immune escape at day 102.  Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003	Pokay DB	https://doi.org/10.1016/j.chom.2021.02.003
S494P	S	False	convalescent_plasma_escape	 S494P frequently engages in interactions with antibodies but not with ACE2. It reduces antibody   neutralization of all 16 convalescent sera tested, averaging WT ratio of 0.41+-0.08 (less dramatic than E484K).   This amino acid emerges as an additional hotspot for immune evasion and a target for therapies, vaccines and diagnostics.  It has emerged independently in multiple lineages.  Alenquer et al. (2021) https://doi.org/10.1101/2021.04.22.441007  In 2 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,   S484P shows a slightly resistent profile across both timepoints (i.e. resistant to immune cell somatic mutation evolution)  Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003	Pokay DB	"https://doi.org/10.1101/2021.04.22.441007;https://doi.org/10.1016/j.chom.2021.02.003"
G446V	S	False	convalescent_plasma_escape	 In 2 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,   the early serum timepoint shows significant resistance (~10x or more), but both abate by the late timepoint (~3m)   presumably through immune cell somatic mutation evolution.  Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003	Pokay DB	https://doi.org/10.1016/j.chom.2021.02.003
G485R	S	False	convalescent_plasma_escape	 In 1 of 11 subjects' convalescent sera in an early+late mutational landscape analysis of the RBD,   this mutation shows significant resistence (~10x) at day 26, but waning resistence at day 102 (presumably due to immune cell somatic mutation evolution).  Greaney et al. (2021) https://doi.org/10.1016/j.chom.2021.02.003	Pokay DB	https://doi.org/10.1016/j.chom.2021.02.003
K417N, E484K, N501Y	S	False	convalescent_plasma_escape	 Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera   collected ~8mo post Jan 2020 first wave in China).  Hu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1  Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.  Alenquer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1"
E484K	S	False	convalescent_plasma_escape	" Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.  Alenquer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1  Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in   IC50 serum dilution concentration for 6 convalescent sera.  Zhou et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1"	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1"
H69del, V70del, N439K	S	False	convalescent_plasma_escape	 No notable change in neutralization efficiency, despite N439K by itself showing a ~2x decrease on average in 16 health workers' convalescent sera.  Alenquer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1
H69del, V70del, N501Y, P681H	S	False	convalescent_plasma_escape	 Slight neutralization improvement on average in 16 health workers' convalescent sera.  Alenquer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1
N439K	S	False	convalescent_plasma_escape	 Observed ~2x decrease on average in 16 health workers' convalescent sera.  Alenquer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1
L452R	S	False	convalescent_plasma_escape	 Observed ~2x decrease on average in 16 health workers' convalescent sera.  Alenquer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1
H69del, V70del, N501Y, P681H	S	False	convalescent_plasma_escape	 One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.  Alenquer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1
L5F, Q1208H	S	False	convalescent_plasma_escape	 Four the convalescent sera tested showed 4-fold or greater improvement in neutralization efficiency.  Alenquer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1
H69del, V70del, N439K	S	False	convalescent_plasma_escape	 One convalescent sera tested showed 4-fold or greater reduction in neutralization efficiency.  Alenquer et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1
S13I, W152C, L452R	S	False	convalescent_plasma_escape	 Antibody neutralization assays showed 6.7-fold resistence against 7/8 convalescent plasma.  Deng et al. (2021) https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1
L242del, A243del, L244del	S	False	convalescent_plasma_escape	 The neutralizing activity of 8/20 convalescent sera was significantly lower against this pseudotyped virus model  Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2	Pokay DB	https://doi.org/10.1038/s41586-021-03398-2
N501Y	S	False	convalescent_plasma_escape	 Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.  Shen et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2  In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both   the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.  Rathnasinghe et al. (2021) https://dx.doi.org/10.1101%2F2021.01.19.21249592	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;https://dx.doi.org/10.1101%2F2021.01.19.21249592"
H69del, V70del	S	False	convalescent_plasma_escape	 Neutralization activity of almost all Moderna Phase 1 sera tested actually *increased*.  Shen et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2
H69del, V70del, Y493F	S	False	convalescent_plasma_escape	 Neutralization activity of almost all convalescent sera tested decreased ~2x.  Shen et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2
S982A	S	False	convalescent_plasma_escape	 The neutralizing activity of 6/20 convalescent sera was significantly lower against this single variant pseudotyped virus model,  showing similar patterns to the pseudotyped virus model of B.1.1.7.  Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2	Pokay DB	https://doi.org/10.1038/s41586-021-03398-2
K417N, E484K, N501Y 	S	False	convalescent_plasma_escape	 Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced  by vaccination or infection, comparable to what was previously shown with monoclonal  antibodies for N501Y and more importantly for E484K. Even though viral mutations  may more strongly affect monoclonal antibodies than sera activity, the latter may also be  reduced as confirmed here.  Vogel et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1  In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples  Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w 	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;https://doi.org/10.1038/s41591-021-01294-w"
E484K, N501Y	S	False	convalescent_plasma_escape	 In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples.   Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w 	Pokay DB	https://doi.org/10.1038/s41591-021-01294-w
K417N	S	False	convalescent_plasma_escape	 In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P=0.0361.  Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w 	Pokay DB	https://doi.org/10.1038/s41591-021-01294-w
E484K	S	False	convalescent_plasma_escape	 Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest  concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments).  Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2  The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model  Wang et al. (2021) https://doi.org/10.1038/s41586-021-03398-2	Pokay DB	"https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;https://doi.org/10.1038/s41586-021-03398-2"
E484A	S	False	convalescent_plasma_escape	 Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest  concentration (1:80 initial dilution) of all 4 convalescent sera tested.  Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
E484D	S	False	convalescent_plasma_escape	 Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest  concentration (1:80 initial dilution) of all 4 convalescent sera tested.  Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
E484G	S	False	convalescent_plasma_escape	 Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest  concentration (1:80 initial dilution) of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
T345A	S	False	convalescent_plasma_escape	 Strong reduction in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
T345N	S	False	convalescent_plasma_escape	 Strong reduction in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
T345S	S	False	convalescent_plasma_escape	 Strong reduction in neutralization capability of all 4 convalescent sera tested (strongest of T345 alts).  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
R346G	S	False	convalescent_plasma_escape	 Improvement in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
A352D	S	False	convalescent_plasma_escape	 Improvement in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
L441R	S	False	convalescent_plasma_escape	 Strong reduction in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
K444E	S	False	convalescent_plasma_escape	 Ablation of neutralization capability of 3/4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
K444N	S	False	convalescent_plasma_escape	 Improvement in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
G446D	S	False	convalescent_plasma_escape	 Decrease in neutralization capability of all 4 convalescent sera tested (1 ablated).  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
G446V	S	False	convalescent_plasma_escape	 Ablation of neutralization capability of 3 convalescent sera tested, 1 improvement.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
N450D	S	False	convalescent_plasma_escape	 Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
N450K	S	False	convalescent_plasma_escape	 Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
N450Y	S	False	convalescent_plasma_escape	 Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations), triple replicates.  Against a broader panel of 16 convalescent plasma (no replicates), reductions in neutralization are considerably less dramatic   in pattern, and sometime neutralization increases.   Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
L452R	S	False	convalescent_plasma_escape	 Ablation of neutralization capability of 3 of 4 convalescent sera tested, the other is significantly hindered.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
S477G	S	False	convalescent_plasma_escape	 Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
S477N	S	False	convalescent_plasma_escape	 Mixed bag of mild positive and negative changes in neutralization capability of all 4 convalescent sera tested.  Against a wider panel of 16 convalescent plasma (no replicates), 10 show low neutralization.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
S477R	S	False	convalescent_plasma_escape	 Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
T478I	S	False	convalescent_plasma_escape	 Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
F486Y	S	False	convalescent_plasma_escape	 Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
F486S	S	False	convalescent_plasma_escape	 Modest decrease in in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
F490S	S	False	convalescent_plasma_escape	 Strong reduction in neutralization capability of all 4 convalescent sera tested (3 ablations).  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
S494P	S	False	convalescent_plasma_escape	 Mixed bag of positive and negative changes in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
P499L	S	False	convalescent_plasma_escape	 General increase in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
T345A, L517R	S	False	convalescent_plasma_escape	 General increase in neutralization capability of all 4 convalescent sera tested.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
S477N, S514F	S	False	convalescent_plasma_escape	 Strong reduction in neutralization capability of all 4 convalescent sera tested (2 ablations).  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
K417N, E484K, N501Y	S	False	convalescent_plasma_escape	" 27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres   Wibmer et al. (2021) https://doi.org/10.1101/2021.01.18.427166"	Pokay DB	https://doi.org/10.1101/2021.01.18.427166
N148S	S	False	convalescent_plasma_escape	 Strong positive selection (up to 72% of supernatant sequences) under six rounds of COV47 convalescent plasma passage  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
K150R	S	False	convalescent_plasma_escape	 Positive selection (up to 18% of supernatant sequences) under two rounds of COV47 convalescent plasma passage  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
K150E	S	False	convalescent_plasma_escape	 Strong positive selection (up to 40% of supernatant sequences) under three rounds of COV47 convalescent plasma passage  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
K150T	S	False	convalescent_plasma_escape	 Positive selection (up to 22% of supernatant sequences) after COV47 convalescent plasma assay  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
K150Q	S	False	convalescent_plasma_escape	 Positive selection (up to 22% of supernatant sequences) under two rounds of COV47 convalescent plasma passage  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
S151P	S	False	convalescent_plasma_escape	 Positive selection (up to 20% of supernatant sequences) under three rounds of COV47 convalescent plasma passage  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
K444R	S	False	convalescent_plasma_escape	 Positive selection (up to 20% of supernatant sequences) under two rounds of COV-NY convalescent plasma passage, eliminated in rounds three and four  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
K444N	S	False	convalescent_plasma_escape	 Positive selection (up to 14% of supernatant sequences) after COV-NY convalescent plasma assay  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
K444Q	S	False	convalescent_plasma_escape	 Positive selection (up to 33% of supernatant sequences) after COV-NY convalescent plasma assay  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
V445E	S	False	convalescent_plasma_escape	 Positive selection (up to 18% of supernatant sequences) after COV-NY convalescent plasma assay  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
D796H,  H69del,  V70del	S	False	convalescent_plasma_escape	 Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma  Kemp et al. (2020) https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1
F140del	S	False	convalescent_plasma_escape	 36% of virions contained this variant (in the S-protein NTD N3 loop) after 7 passages (45 days) in convalescent plasma PT188  This variant became 100% in subsequent passage with decreased neutralizing titer.  It is hypothesized that the F140 deletion alters the packing of the N1, N3 and N5 loops  Andreano et al. (2020) https://www.biorxiv.org/content/10.1101/2020.12.28.424451	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.12.28.424451
E484K	S	False	convalescent_plasma_escape	 This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity  Andreano et al. (2020) https://www.biorxiv.org/content/10.1101/2020.12.28.424451	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.12.28.424451
Y145del	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
Q414E	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
N439K	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
G446V	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
K458N	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
I472V	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
A475V	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
T478I	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
V483I	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
F490L	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Resistent to 3 individual sera at >4x  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
H519P	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Resistent to 3 individual sera at >4x  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
A831V	S	False	convalescent_plasma_escape	 Resistant to a pool of 10 convalescent sera (but less than 4x, a typical threshold for definition of escape)  Li et al. (2020) https://doi.org/10.1016/j.cell.2020.07.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.07.012
N501Y	S	False	environmental_condition_stability	 Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
S982A	S	False	environmental_condition_stability	 Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, N501Y, P681H	S	False	environmental_condition_stability	 Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 1 hour.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
Y365W	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.99 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.79 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.75 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367F	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.74 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.74 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I358F	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.72 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L518D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.7 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L518E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.68 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K417V	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.65 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N354E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.64 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.64 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.58 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.58 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.56 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.56 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V524R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.54 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.54 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R408D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.53 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N354Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.52 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y365F	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.48 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S373N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.48 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F456Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.48 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.46 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.45 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q498D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.45 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I358W	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.41 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527L	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.41 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.41 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.4 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A348P	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.4 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K417I	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.39 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K529A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.38 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.37 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.36 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S383D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.36 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S477E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.36 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.36 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L518K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.35 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S373K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.35 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.34 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V362T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.33 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N501M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.33 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.32 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369L	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.31 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.31 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.31 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q414A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.3 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G339D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.3 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.3 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y365L	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.3 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527C	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.3 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V483T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.3 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G504D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.3 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L518S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.29 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P337D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.29 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A520G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.29 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L517N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.29 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R408Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.29 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y449D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.29 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367W	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.28 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
T385E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.28 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.28 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P337N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.28 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N360D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.28 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F486E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.28 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.28 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.28 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.27 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.27 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
H519D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.27 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R408E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.27 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F392W	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.26 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V362Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.26 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I358M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.26 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.26 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A363W	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.25 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L441I	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.25 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.25 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A372K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.25 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P521N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.25 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K417T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.25 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.25 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502P	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.25 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L518T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.24 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.24 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N440E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.23 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455C	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.23 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S366D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.22 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
H519N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.22 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K529G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.22 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527I	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.22 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S383N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.22 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G526K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.22 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F486P	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.22 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F486Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.22 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S530E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N354K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K356R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V341I	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369V	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
T385D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L441Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
E516Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R408S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455V	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.21 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L390Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.2 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A522Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.2 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
C391N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.2 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369F	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.2 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A372Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.2 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S383E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.19 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.19 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.19 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.19 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F464Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.19 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
C525D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.19 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527W	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.19 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.19 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R357K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.18 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P384K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.18 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.18 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K386E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.18 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K528N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.18 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
D428N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.18 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S359T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.18 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F486K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.18 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y449Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.18 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N354S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.17 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.17 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S530A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.17 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S459Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.17 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I468T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.17 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K417L	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.17 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A475N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.17 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q498H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N460K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K378R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527V	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I434F	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K529H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G339E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
T430V	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.16 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R346T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R346N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L441V	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367L	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G339H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K529T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K386D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R408P	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N450E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F486R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N487Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.15 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y508H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N354R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V483K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K356T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I358L	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K528G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N501Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I332G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G496K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.14 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
T415H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L518N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K529S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N354D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F486S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F486T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455P	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G496R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.13 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S477D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S373Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369I	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S366E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S514T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R346K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S359H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S366A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367I	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R408A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G496S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y449H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y449S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G496T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y449E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505C	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.12 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L335E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
D389E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G339N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S459E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K529C	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L518C	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y489H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F456H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F486D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.11 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N501W	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F490Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y365M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S530I	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I402V	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I358Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S459K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V362S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V445D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K417H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F486A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K417N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N487G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502V	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.1 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L517M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L335P	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N460R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K386Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S459T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S373E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V483A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A522Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R408G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G504E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y449T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.09 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V483Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K529F	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G339S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V367N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A372E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
T531G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R346E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K528A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369W	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V483S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K417R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N450T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N501D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.08 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
T430I	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
H519P	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
E406H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K529Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L455I	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N460P	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I332Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V362K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N440D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K444T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I468V	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
T385K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S383Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N501A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S530G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K417Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K529R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V503E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F486V	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G496A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
N487D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y449N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y449P	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y505M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.07 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q498Y	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q493A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S530N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S477N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F347W	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V395I	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
R408K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L517T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L518Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
T531N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F374W	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
T376H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P384M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F338L	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L441M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V445E	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K417M	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
T500G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y449G	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y489S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.06 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q498F	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S359Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S366N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I332H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A372R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V445P	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A520P	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
E471D	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
P527N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K529I	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
I332N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S373T	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S373R	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
L452F	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S530C	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
V362Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y369S	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
K386A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
S514V	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q498A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G413N	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
F486H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Y449A	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G496Q	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
Q498K	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
G502H	S	False	gene_expression_increase	Experimentally, Spike gene expression increased 0.05 fold Starr et al. (2020) https://doi.org/10.1016/j.cell.2020.08.012	Pokay DB	https://doi.org/10.1016/j.cell.2020.08.012
A222V	S	False	humoral_response_durability	 27yo female nurse reinfected in December 2020 (B.1.177) after initial infection in March 2020 (B.3), i.e. with a   9 month interval. Both cases were mild.  No significant differences in the neutralizing capacity of the two lineages were observed in 4 sera taken (1 pre-reinfection,   three post-reinfection). Neutralizing antibody titres (IC50) before and immediately after re-infection were <300 against   both strains, and jumped >7x upon re-infection. Viral titres were also higher in the second case.  Second case also includes N:p.A220V  Brehm et al. (2021) https://dx.doi.org/10.3390%2Fv13040661	Pokay DB	https://dx.doi.org/10.3390%2Fv13040661
L141del, G142del	S	False	immunosuppression_variant_emergence	 Deletion that include and extend 141-142 appeared de novo in two of three children with impaired humoral immunity   and persistent SARS-CoV-2 infection subject to sequencing. In both cases appearing and persisting in some form from day >=120.  [This is a common site of deletions in VOCs, such as Y144del in B.1.1.7 and overlapping deletions in P.3, AT.1)]  Truong et al. (2021) https://dx.doi.org/10.1016%2Fj.ebiom.2021.103355	Pokay DB	https://dx.doi.org/10.1016%2Fj.ebiom.2021.103355
D138H, E554D	S	False	immunosuppression_variant_emergence	 Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including  this combination in Spike.  Landis et al. (2021) https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1
L243del, A244del, Q493R	S	False	immunosuppression_variant_emergence	 Dominant (70%) in day 21 of prolonged infection in immunocompromised host on tacrolimus, steroids and convalescent   plasma therapy, then nearly disappearing (<5%) by day 27.  Chen et al. (2021) https://doi.org/10.1101/2021.04.08.21254791	Pokay DB	https://doi.org/10.1101/2021.04.08.21254791
L141del, G142del, V143del, Y144del, E484K	S	False	immunosuppression_variant_emergence	 Individual variants appearing at <=30% frequency at day 21 in immunocompromised host on tacrolimus, steroids and convalescent   plasma therapy, then appearing all at >95% frequency at day 27.  Chen et al. (2021) https://doi.org/10.1101/2021.04.08.21254791	Pokay DB	https://doi.org/10.1101/2021.04.08.21254791
Y453F, H69del, V70del	S	False	immunosuppression_variant_emergence	" The so-called ""delta F"" variant combination previously observed in mink spillover events also emerged in a lymphoma   patient (non-Hodgkin diffuse B-cell lymphoma IV stage B) with a long-term COVID-19 infection (4 months) where 18 de novo mutation occureed overall.  Patient was taking rituximab, the B-cell-depleting agent, and had no detectable neutralizing antibody response.  Bazykin et al. (2021) https://virological.org/t/emergence-of-y453f-and-69-70hv-mutations-in-a-lymphoma-patient-with-long-term-covid-19/580"	Pokay DB	https://virological.org/t/emergence-of-y453f-and-69-70hv-mutations-in-a-lymphoma-patient-with-long-term-covid-19/580
L141del, G142del, V143del, Y144del	S	False	immunosuppression_variant_emergence	 Emergent as 100% variant from larger minor (1% allele frequency) deletion by day 70 post-infection of female immunocompromised   individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia. Variant disappeared after convalescent plasma treatment (day 71)  in subsequent sample sequencing.  Avanzato et al. (2020) https://doi.org/10.1016%2Fj.cell.2020.10.049	Pokay DB	https://doi.org/10.1016%2Fj.cell.2020.10.049
Q183H	S	False	immunosuppression_variant_emergence	 Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome  Choi et al. (2020) https://www.nejm.org/doi/full/10.1056/NEJMc2031364	Pokay DB	https://www.nejm.org/doi/full/10.1056/NEJMc2031364
N501Y	S	False	immunosuppression_variant_emergence	 Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome  Choi et al. (2020) https://www.nejm.org/doi/full/10.1056/NEJMc2031364	Pokay DB	https://www.nejm.org/doi/full/10.1056/NEJMc2031364
T478K, S494P	S	False	immunosuppression_variant_emergence	 Combination of RBD mutations appeared (day 75) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome  complicated by diffuse alveolar hemorrhage, who was receiving anticoagulation therapy, glucocorticoids, cyclophosphamide, and intermittent rituximab and eculizumab.   Choi et al. (2020) https://www.nejm.org/doi/full/10.1056/NEJMc2031364	Pokay DB	https://www.nejm.org/doi/full/10.1056/NEJMc2031364
I870V	S	False	immunosuppression_variant_emergence	 Appeared (day 75) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome  Appeared at same time as T478K,S494P but listed separately due to distance and different domains affected in the Spike (i.e. putatively an independent  mutation from a functional standpoint since the former are from S1, the latter from S2).  Choi et al. (2020) https://www.nejm.org/doi/full/10.1056/NEJMc2031364	Pokay DB	https://www.nejm.org/doi/full/10.1056/NEJMc2031364
Q493K	S	False	immunosuppression_variant_emergence	 Intermittent appearance at Day 128 onward of long infection in patient on escalated immunosupressed starting Day 111  Choi et al. (2020) https://dx.doi.org/10.1056/NEJMc2031364	Pokay DB	https://dx.doi.org/10.1056/NEJMc2031364
Y489H	S	False	immunosuppression_variant_emergence	 Based on structural modelling, this change detected on day 128 sequencing in a chronically infected patient   would alter an extensive network of polar interactions with antibody residue R94VH,   a germline antibody residue that is conserved in all of the potent VH3-53/3-66-derived antibodies isolated from a convalescent donor  5 weeks after infection.  Clark et al. (2021) https://dx.doi.org/10.1016%2Fj.cell.2021.03.027	Pokay DB	https://dx.doi.org/10.1016%2Fj.cell.2021.03.027
H69del, V70del	S	False	immunosuppression_variant_emergence	 The delH69/V70 enhances viral infectivity, indicating its effect on virus fitness is independent to the N501Y RBM change [with which it is found in lineage B.1.1.7]  Possibly arisen as a result of the virus evolving from immune selection pressure in infected individuals and possibly only one chronic infection in the case of lineage B.1.1.7.  Kemp et al. (2020) https://doi.org/10.1101/2020.12.14.422555	Pokay DB	https://doi.org/10.1101/2020.12.14.422555
K444R	S	False	monoclonal_antibody_serial_passage_escape	 Identified in 6/20 replicates of recombinant VSV growth in the presence of mAb COV2-2130.  Dong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.27.428529v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.27.428529v2
K444E	S	False	monoclonal_antibody_serial_passage_escape	 Identified in 2/20 replicates of recombinant VSV growth in the presence of mAb COV2-2130.  Dong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.27.428529v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.27.428529v2
R346I	S	False	monoclonal_antibody_serial_passage_escape	 Provides ~80% escape from mAb COV2-2130, even though its appearance in culture is formed without selective mAb pressure.  Dong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.27.428529v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.27.428529v2
E484K, R346K	S	False	monoclonal_antibody_serial_passage_escape	 In serial experiment of mAb 2B04 resistent mutation isolate E484K then selected against mAb 2H04,  this combination caused escape from both mAbs, even though incubation simultaneously with both  mAbs failed to yield this combination.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
E484K, A372T	S	False	monoclonal_antibody_serial_passage_escape	 In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04,  this combination caused escape from both mAbs, even though incubation simultaneously with both  mAbs failed to yield this combination.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
E484K, K444E	S	False	monoclonal_antibody_serial_passage_escape	 In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04,  this combination caused escape from both mAbs, even though incubation simultaneously with both  mAbs failed to yield this combination.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
E484A, T345A	S	False	monoclonal_antibody_serial_passage_escape	 In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04,  this combination caused escape from both mAbs, even though incubation simultaneously with both  mAbs failed to yield this combination.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
E484K, R346G	S	False	monoclonal_antibody_serial_passage_escape	 In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04,  this combination caused escape from both mAbs, even though incubation simultaneously with both  mAbs failed to yield this combination.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
E484K, K444E	S	False	monoclonal_antibody_serial_passage_escape	 In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04,  this combination caused escape from both mAbs, even though incubation simultaneously with both  mAbs failed to yield this combination.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2
N460K	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460T	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460L	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460R	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460I	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460A	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460F	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460V	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460M	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460P	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460H	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1  Mild escape mutant emergent for class 1 antibody C613 in vitro.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
N460S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460C	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N460Y	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F456H	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F456S	S	False	monoclonal_antibody_serial_passage_escape	 C666 mildly selected for the emergence of the F456S mutation in vitro.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
F456G	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F456R	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F456Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F456A	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F456C	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F456K	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F456V	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1  Moderate in vitro selection against class 1 (Spike 'up' conformation) antibodies C683 and C664.  Unclassified antibody C666  selected for the emergence of the F456V mutation in vitro.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
F456T	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
L455E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
L455R	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
L455W	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
L455N	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
L455G	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
L452R	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
L452D	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
L452K	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
L452E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
I472W	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
I472G	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
I472K	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
I472D	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab),  and combination treatment with LY-CoV016, but moderate decrease in ACE2 binding affinity.  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y473Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y473I	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y473C	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y473V	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y473E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y473S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y473T	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y473L	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y473N	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y473M	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y473A	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
V483R	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
V483K	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
V483E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
E484F	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G485P	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab),   and in combination with LY-CoV016 (i.e. proline stiffness disrupts binding sites for both antibodies), but moderate   decrease in ACE2 binding affinity.  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G485R	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G485N	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G485K	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G485T	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G485D	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
P9S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2L28, S2M28, S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
P9Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2M28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
S12P	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28, S2X333  Putative mechanism of action is the introduction of a new signal peptide, altering  cleavage to occur between residues C15 and V16, thereby eliminating the C15-C136  disulfide bond â€“ similarly to escape mutants at positions C15 and C136  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
C15F	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2M28  Eliminates the C15-C136 disulfide bond.  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
C15R	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2M28  Eliminates the C15-C136 disulfide bond.  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
C15W	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28  Eliminates the C15-C136 disulfide bond.  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
C15S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X333  Eliminates the C15-C136 disulfide bond.  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
C15Y	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X333  Eliminates the C15-C136 disulfide bond.  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
L18P	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against all tested Spike N terminal domain antigenic supersite i mAbs S2L28, S2M28, S2X28, S2X333  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
T22P	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
Y28C	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2M28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
K77E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
D80N	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
A123T	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2M28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
C136G	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
C136S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X333  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
C136Y	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X333  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
P139S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
P139Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
F140S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2L28, S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475  Selected once in passage with mAb COV2-2676.  Suryadevara et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1	Pokay DB	"https://doi.org/10.1101/2021.01.14.426475;https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1"
A123S	S	False	monoclonal_antibody_serial_passage_escape	 Selected in passage with mAb COV2-2489 during alanine mutagenesis antibody mapping experiment.  Suryadevara et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1
G142A	S	False	monoclonal_antibody_serial_passage_escape	 Selected in passage with mAb COV2-2489 during alanine mutagenesis antibody mapping experiment.  Suryadevara et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1
F157A	S	False	monoclonal_antibody_serial_passage_escape	 Selected in passage with mAb COV2-2489 during alanine mutagenesis antibody mapping experiment.  Suryadevara et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1
N164A	S	False	monoclonal_antibody_serial_passage_escape	 Selected in passage with mAb COV2-2489 during alanine mutagenesis antibody mapping experiment.  Suryadevara et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1
Y144A	S	False	monoclonal_antibody_serial_passage_escape	 Selected in passage with mAb COV2-2676 during alanine mutagenesis antibody mapping experiment.  Suryadevara et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1
R158S	S	False	monoclonal_antibody_serial_passage_escape	 Selected three times in passage with mAb COV2-2489.  Suryadevara et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1
F140C	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X333  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
L141S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28   McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
G142D	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28, S2X333  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475  Selected twice in passage with mAb COV2-2489.  Suryadevara et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1	Pokay DB	"https://doi.org/10.1101/2021.01.14.426475;https://www.biorxiv.org/content/10.1101/2021.01.19.427324v1"
G142C	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
Y144N	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
Y144C	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
K147Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
K147T	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X333  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
K147E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2X28, S2X333  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
R158G	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
L244S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
R246G	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAbs S2M28, S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475 	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
S247R	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
P251L	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
G252D	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
G252C	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
D253E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
D253G	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
S255F	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475 	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
G257S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
W258R	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against Spike N terminal domain antigenic supersite i mAb S2L28  McCallum et al. (2021) https://doi.org/10.1101/2021.01.14.426475 	Pokay DB	https://doi.org/10.1101/2021.01.14.426475
C361H	S	False	monoclonal_antibody_serial_passage_escape	 Most and modestly potent escape variant for this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Eliminates the C15-C136 disulfide bond.  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
S443Q	S	False	monoclonal_antibody_serial_passage_escape	 Most potent escape variant for this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
S443H	S	False	monoclonal_antibody_serial_passage_escape	 Second most potent escape variant for this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
S443Y	S	False	monoclonal_antibody_serial_passage_escape	 Mostand highly effective escape variant in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
S443K	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective escape variant in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
S443M	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective escape variant in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
S443F	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective escape variant in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378L	S	False	monoclonal_antibody_serial_passage_escape	 Most potent escape variant for this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Ranked escape variant in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378V	S	False	monoclonal_antibody_serial_passage_escape	 Second most potent escape variant for this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Second most potent escape variant for this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
V382Y	S	False	monoclonal_antibody_serial_passage_escape	 Most and fairly potent escape variant for this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
V382A	S	False	monoclonal_antibody_serial_passage_escape	 Second most potent escape variant for this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
S383L	S	False	monoclonal_antibody_serial_passage_escape	 Most and highly potent escape variant for this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
S383K	S	False	monoclonal_antibody_serial_passage_escape	 Highly ranked escape variant in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
S383Y	S	False	monoclonal_antibody_serial_passage_escape	 Highly ranked escape variant in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
S383F	S	False	monoclonal_antibody_serial_passage_escape	 Highly ranked escape variant in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
S383E	S	False	monoclonal_antibody_serial_passage_escape	 Highly ranked escape variant in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
P384K	S	False	monoclonal_antibody_serial_passage_escape	 Most potent escape variant for this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F338L	S	False	monoclonal_antibody_serial_passage_escape	 Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2)  Long et al. (2020) https://doi.org/10.1128/mBio.02707-20	Pokay DB	https://doi.org/10.1128/mBio.02707-20
S373P	S	False	monoclonal_antibody_serial_passage_escape	 Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2)  Long et al. (2020) https://doi.org/10.1128/mBio.02707-20	Pokay DB	https://doi.org/10.1128/mBio.02707-20
R408T	S	False	monoclonal_antibody_serial_passage_escape	 Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2)  Long et al. (2020) https://doi.org/10.1128/mBio.02707-20  PG: this finding was NOT recapitulated for the same antibody in Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	"https://doi.org/10.1128/mBio.02707-20;https://doi.org/10.1016/j.chom.2020.11.007"
F392K	S	False	monoclonal_antibody_serial_passage_escape	 Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2)  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F392Y	S	False	monoclonal_antibody_serial_passage_escape	 Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2)  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F392Q	S	False	monoclonal_antibody_serial_passage_escape	 Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2)  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F392A	S	False	monoclonal_antibody_serial_passage_escape	 Reduce affinity for mildly cross-reactive CR3022 (2003 pandemic SARS monoclonal antibody cross-reactive to SARS-CoV-2)  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K417D	S	False	monoclonal_antibody_serial_passage_escape	 Most and moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Mildly effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV016, but moderate decrease in ACE2 binding affinity  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
K417E	S	False	monoclonal_antibody_serial_passage_escape	 Moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Mildly effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV016, with modest loss of ACE2 binding affinity.  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1  In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibodies C614, C660, C664, C683, and to a lesser extent C678.  In vitro selection against class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C653.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
N501Y	S	False	monoclonal_antibody_serial_passage_escape	 In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
N501H	S	False	monoclonal_antibody_serial_passage_escape	 Mild in vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C613.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
N501T	S	False	monoclonal_antibody_serial_passage_escape	 Mild in vitro selection against class 3 monoclonal antibody C670.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
V503L	S	False	monoclonal_antibody_serial_passage_escape	 Mild in vitro selection against class 3 monoclonal antibody C669.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
Y508H	S	False	monoclonal_antibody_serial_passage_escape	 Mild in vitro selection against class 3 monoclonal antibody C669.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
G504D	S	False	monoclonal_antibody_serial_passage_escape	 Moderate in vitro selection against both class 3 monoclonal antibodies tested: C669 and C670.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
K417G	S	False	monoclonal_antibody_serial_passage_escape	 Moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
K417F	S	False	monoclonal_antibody_serial_passage_escape	 Moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
K417I	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
K417N	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1  In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
K417A	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
K417V	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
K417L	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
K417Y	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
K417P	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
K417H	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
K417T	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1  In vitro selection against class 1 antibody C682  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
K417W	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
K417C	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
K417S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
K417M	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
K417Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A411K	S	False	monoclonal_antibody_serial_passage_escape	 Only (and moderately) effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Most and moderately effective mutant against this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
Y365E	S	False	monoclonal_antibody_serial_passage_escape	 Most and moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
Y365K	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
Y369N	S	False	monoclonal_antibody_serial_passage_escape	 Most and moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
Y369P	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
Y369D	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
N370P	S	False	monoclonal_antibody_serial_passage_escape	 Most and moderately effective mutant against this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
A372S	S	False	monoclonal_antibody_serial_passage_escape	 Most and moderately effective mutant against this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
A372T	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F374D	S	False	monoclonal_antibody_serial_passage_escape	 Most and moderately effective mutant against this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F374N	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378E	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378V	S	False	monoclonal_antibody_serial_passage_escape	 Second most moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378S	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378Q	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Ranked mildly effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378A	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378I	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378T	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378L	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378N	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378Y	S	False	monoclonal_antibody_serial_passage_escape	 Most effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378D	S	False	monoclonal_antibody_serial_passage_escape	 Most and moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked modestly effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
P384Y	S	False	monoclonal_antibody_serial_passage_escape	 Most and moderately effective mutant against this position in the RBD for mildly cross-reactive (2003 SARS) monoclonal antibody CR3022  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
P384E	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
P384D	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
P384N	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
P384K	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
P384H	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
P384G	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
P384Q	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
P384R	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for mildly neutralizing COV2-2677 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
T376E	S	False	monoclonal_antibody_serial_passage_escape	 Most effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Most and moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
T376F	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked modestly effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
T376D	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
T376N	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
T376W	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked modestly effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
T376R	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
K378H	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2094 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
R408D	S	False	monoclonal_antibody_serial_passage_escape	 Highly effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
R408E	S	False	monoclonal_antibody_serial_passage_escape	 Moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
A435W	S	False	monoclonal_antibody_serial_passage_escape	 Only effective mutant against this position in the RBD for moderately neutralizing COV2-2084 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
D420R	S	False	monoclonal_antibody_serial_passage_escape	 Most (tied) and moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2165 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
D420W	S	False	monoclonal_antibody_serial_passage_escape	 Most (tied) and moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2165 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
D420Y	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildy effective mutant against this position in the RBD for moderately neutralizing COV2-2165 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
D420K	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildy effective mutant against this position in the RBD for moderately neutralizing COV2-2165 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
D420Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
D420N	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
D420M	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
D420A	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
D420E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A475Y	S	False	monoclonal_antibody_serial_passage_escape	 Most and mildly effective mutant against this position in the RBD for moderately neutralizing COV2-2165 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
A475R	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for moderately neutralizing COV2-2165 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
A475E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A475I	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A475E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A475K	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A475F	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A475D	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A475Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A475M	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A475V	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A475N	S	False	monoclonal_antibody_serial_passage_escape	 Only and moderately effective mutant against this position in the RBD for moderately neutralizing COV2-2082 monoclonal antibody  Ranked mildly effective mutant against this position in the RBD for moderately neutralizing COV2-2165 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G476T	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G476E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G476R	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G476K	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
E484G	S	False	monoclonal_antibody_serial_passage_escape	 Class 2 mAb C602 mildly selected for the emergence of this mutation in vitro.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
E484M	S	False	monoclonal_antibody_serial_passage_escape	 Most but stiil only mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Most and moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E484V	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E484H	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E484Y	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E484F	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E484L	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E484I	S	False	monoclonal_antibody_serial_passage_escape	 Most btu only mildly effective ranked mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
E484R	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E484W	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
E484C	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E484A	S	False	monoclonal_antibody_serial_passage_escape	" ""E484A rose in frequency in linkage with F486I, but since E484A is not an escape mutation in our maps it is not shown in other panels""  Starr et al. (2020) https://doi.org/10.1101/2020.11.30.405472  Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"	Pokay DB	"https://doi.org/10.1101/2020.11.30.405472;https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E484N	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E484P	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E484I	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
E484Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
E484D	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1  Class 2 mAb C602 mildly selected for the emergence of this mutation in vitro.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
G446V	S	False	monoclonal_antibody_serial_passage_escape	 Most effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Most but only mildly effective mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G446P	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G446D	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G446F	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G446E	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G446T	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G446W	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G446H	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G446N	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G446Y	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G446L	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447P	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Most but only mildly effective mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447N	S	False	monoclonal_antibody_serial_passage_escape	 Most effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447Y	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447L	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447I	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447H	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447M	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447K	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447V	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447E	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447T	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447S	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447R	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447C	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447F	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G447D	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
Y449R	S	False	monoclonal_antibody_serial_passage_escape	 Ranked most but only mildy effective mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
N448C	S	False	monoclonal_antibody_serial_passage_escape	 Ranked most and moderately effective mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
N4348R	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
N448P	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
E484T	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
E406W	S	False	monoclonal_antibody_serial_passage_escape	 Only observed effective escape variant against Regeron's antibody cocktail (REGN10933 and REGN10987)   Starr et al. (2020) https://www.biorxiv.org/content/10.1101/2020.11.30.405472	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.11.30.405472
G496V	S	False	monoclonal_antibody_serial_passage_escape	 Most effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496D	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496Y	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496R	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496F	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496E	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496Q	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496I	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496W	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496L	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496K	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496N	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496T	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496M	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
G496H	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
E484K	S	False	monoclonal_antibody_serial_passage_escape	 Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)  Baum et al. (2020) http://dx.doi.org/10.1126/science.abd0831  Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages  Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf  The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).  Barnes et al. (2020) https://doi.org/10.1038/s41586-020-2852-1  Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1  Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"http://dx.doi.org/10.1126/science.abd0831;https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;https://doi.org/10.1038/s41586-020-2852-1;https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
N439K	S	False	monoclonal_antibody_serial_passage_escape	 Class 3 antibody C669 and C670 mildly selected for the emergence of the N439K mutation in vitro.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
N440K	S	False	monoclonal_antibody_serial_passage_escape	 Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
F490A	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F490E	S	False	monoclonal_antibody_serial_passage_escape	 Most effective mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
F490L	S	False	monoclonal_antibody_serial_passage_escape	 Positive selection (up to 23% of supernatant sequences) after C121 monoclonal antibody assay  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
F490D	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody  Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
F490K	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096 monoclonal antibody  Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
F490N	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
F490V	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F490S	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1  Class 2/3 mAb C603 modestly selected for the emergence of this mutation in vitro.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
F490P	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
F490R	S	False	monoclonal_antibody_serial_passage_escape	 Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody  Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F490G	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F490T	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
S494R	S	False	monoclonal_antibody_serial_passage_escape	 Most but only mildly effective mutant against this position in the RBD for highly neutralizing COV2-2496 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
S494K	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
S494P	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
S494W	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Q493K	S	False	monoclonal_antibody_serial_passage_escape	 Escapes mAb REGN10987, part of Regeneron's antibody cocktail.   Starr et al. (2020) https://doi.org/10.1101/2020.11.30.405472  Strong positive selection (up to 45% of supernatant sequences) under two rounds of C121 monoclonal antibody passage  Strong positive selection (up to 39% of supernatant sequences) after two rounds of C135 monoclonal antibody passage, overall 76% switch away from Q493 to K or R  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1101/2020.11.30.405472;https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
N440K	S	False	monoclonal_antibody_serial_passage_escape	 Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
R346S	S	False	monoclonal_antibody_serial_passage_escape	 Positive selection (up to 30% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf  The engineered mutation cause 10-fold or more increase in the disassociation constant with C135 and C110 monoclonal antibodies vs. wild type Spike protein RBD domain AAs.	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
R346K	S	False	monoclonal_antibody_serial_passage_escape	 Strong positive selection (up to 53% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, overall 70% switch away from R346 to S, K or M  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf	Pokay DB	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf
Q493R 	S	False	monoclonal_antibody_serial_passage_escape	 Strong positive selection (up to 37% of supernatant sequences) after two rounds of C135 monoclonal antibody passage, overall 76% switch away from Q493 to K or R  Weisblum et al. (2020) https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf  The engineered mutation cause 10-fold or more increase in the disassociation constant with C144, C002 and C121 monoclonal antibodies vs. wild type Spike protein RBD domain AAs.  Barnes et al. (2020) https://doi.org/10.1038/s41586-020-2852-1  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1  Class 2 mAb C627 modestly selected for the emergence of this mutation in vitro.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;https://doi.org/10.1038/s41586-020-2852-1;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
Q493Y	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Q493F	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Q493W	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
A475V	S	False	monoclonal_antibody_serial_passage_escape	 The engineered mutation cause 10-fold or more increase in the disassociation constant with C102, C105 and C144 monoclonal antibodies vs. wild type Spike protein RBD domain AAs.  Barnes et al. (2020) https://doi.org/10.1038/s41586-020-2852-1	Pokay DB	https://doi.org/10.1038/s41586-020-2852-1
K444Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape variant 45% appearance in 2 passages against Regeneron monoclonal antibody RGN10987 @ 10ug/mL  Baum et al. (2020) http://dx.doi.org/10.1126/science.abd0831	Pokay DB	http://dx.doi.org/10.1126/science.abd0831
V445A	S	False	monoclonal_antibody_serial_passage_escape	 Escape variant 41% appearance in 2 passages against Regeneron monoclonal antibody RGN10987 @ 10ug/mL  Baum et al. (2020) http://dx.doi.org/10.1126/science.abd0831	Pokay DB	http://dx.doi.org/10.1126/science.abd0831
V445G	S	False	monoclonal_antibody_serial_passage_escape	 Most and highly effective mutant against this position in the RBD for highly neutralizing COV2-2499  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
V445N	S	False	monoclonal_antibody_serial_passage_escape	 Ranked highly effective mutant against this position in the RBD for highly neutralizing COV2-2499  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
V445W	S	False	monoclonal_antibody_serial_passage_escape	 Ranked highly effective mutant against this position in the RBD for highly neutralizing COV2-2499  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
V445D	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
V445Y	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
V445K	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
V445R	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2499  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
V445S	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2499  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
N450D	S	False	monoclonal_antibody_serial_passage_escape	 Escape variant 95% appearance in 2 passages against Regeneron monoclonal antibody RGN10934 @ 50ug/mL  Baum et al. (2020) http://dx.doi.org/10.1126/science.abd0831	Pokay DB	http://dx.doi.org/10.1126/science.abd0831
L452Y	S	False	monoclonal_antibody_serial_passage_escape	 Most effective mutant against this position in the RBD for highly neutralizing COV2-2096  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
L452W	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
L452K	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
L452R	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Class 2/3 antibody C628 and class 2 antibody C643 selected for the emergence of the L452R mutation in vitro.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2"
L452T	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
L452E	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
L452F	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2096  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
N450Y	S	False	monoclonal_antibody_serial_passage_escape	 Most effective mutant against this position in the RBD for highly neutralizing COV2-2096  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
N450T	S	False	monoclonal_antibody_serial_passage_escape	 Ranked effective mutant against this position in the RBD for highly neutralizing COV2-2096  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
N450P	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2096  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
N450G	S	False	monoclonal_antibody_serial_passage_escape	 Ranked mildly effective mutant against this position in the RBD for highly neutralizing COV2-2096  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F486V	S	False	monoclonal_antibody_serial_passage_escape	 Escape variant 88% appearance in 2 passages against Regeneron monoclonal antibody RGN10933 @ 50ug/mL  Baum et al. (2020) http://dx.doi.org/10.1126/science.abd0831  Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	"http://dx.doi.org/10.1126/science.abd0831;https://doi.org/10.1016/j.chom.2020.11.007"
F486A	S	False	monoclonal_antibody_serial_passage_escape	 Most effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F486C	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F486G	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
F486K	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F486R	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F486S	S	False	monoclonal_antibody_serial_passage_escape	 Ranked moderately effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F486D	S	False	monoclonal_antibody_serial_passage_escape	 Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
F486V	S	False	monoclonal_antibody_serial_passage_escape	 Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
F486T	S	False	monoclonal_antibody_serial_passage_escape	 Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
F486P	S	False	monoclonal_antibody_serial_passage_escape	 Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
Y489H	S	False	monoclonal_antibody_serial_passage_escape	 Escapes mAb REGN10933 (part of Regeneron's antibody cocktail)  Starr et al. (2020) https://doi.org/10.1101/2020.11.30.405472  Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1101/2020.11.30.405472;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
Y489V	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y489L	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y489Q	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y489M	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y489I	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
Y489W	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G504I	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G504V	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G504C	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
G504L	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, minimal ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
F486I	S	False	monoclonal_antibody_serial_passage_escape	 Escapes mAb REGN10933 (part of Regeneron's antibody cocktail)  Starr et al. (2020) https://doi.org/10.1101/2020.11.30.405472  Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1101/2020.11.30.405472;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
F486L	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N440D	S	False	monoclonal_antibody_serial_passage_escape	 Escapes mAb REGN10987 (part of Regeneron's antibody cocktail)  Starr et al. (2020) https://doi.org/10.1101/2020.11.30.405472	Pokay DB	https://doi.org/10.1101/2020.11.30.405472
N487Y	S	False	monoclonal_antibody_serial_passage_escape	 Most effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
N487S	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N487T	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N487A	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N487E	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N487K	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N487H	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N487L	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N487F	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N487D	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N487G	S	False	monoclonal_antibody_serial_passage_escape	 Escape mutation against monoclonal antibody LY-CoV016, moderate ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1
N487R	S	False	monoclonal_antibody_serial_passage_escape	 Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007	Pokay DB	https://doi.org/10.1016/j.chom.2020.11.007
N487Q	S	False	monoclonal_antibody_serial_passage_escape	 Ranked modestly effective mutant against this position in the RBD for highly neutralizing COV2-2832 monoclonal antibody  Greaney et al. (2020) https://doi.org/10.1016/j.chom.2020.11.007  Weak escape mutation against monoclonal antibody LY-CoV016, high ACE2 binding affinity loss  Starr et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1	Pokay DB	"https://doi.org/10.1016/j.chom.2020.11.007;https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1"
R685S	S	False	monoclonal_antibody_serial_passage_escape	 Escape variant 47% appearance in 2 passages against Regeneron monoclonal antibody RGN10987 @ 10ug/mL  Baum et al. (2020) http://dx.doi.org/10.1126/science.abd0831	Pokay DB	http://dx.doi.org/10.1126/science.abd0831
G769E	S	False	monoclonal_antibody_serial_passage_escape	 Escape variant 87% appearance in 2 passages against Regeneron monoclonal antibody RGN10933 @ 50ug/mL  Baum et al. (2020) http://dx.doi.org/10.1126/science.abd0831	Pokay DB	http://dx.doi.org/10.1126/science.abd0831
Q779K	S	False	monoclonal_antibody_serial_passage_escape	 Escape variant 20% appearance in 2 passages against Regeneron monoclonal antibody RGN10989 @ 50ug/mL  Baum et al. (2020) http://dx.doi.org/10.1126/science.abd0831	Pokay DB	http://dx.doi.org/10.1126/science.abd0831
E484K, N501Y	S	False	pharmaceutical_effectiveness	 Omicron BA.4 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared   to D614G  Neerukonda et al. (2022) https://outbreak.info/resources/2022.06.01.494385	Pokay DB	https://outbreak.info/resources/2022.06.01.494385
E484K, N501Y	S	False	pharmaceutical_effectiveness	 Omicron BA.5 have higher sensitivity to inhibition by soluble angiotensin converting enzyme 2 (ACE2) and the endosomal inhibitor chloroquine compared   to D614G  Neerukonda et al. (2022) https://outbreak.info/resources/2022.06.01.494385	Pokay DB	https://outbreak.info/resources/2022.06.01.494385
E484K, N501Y	S	False	pharmaceutical_effectiveness	 Out of 10 individuals with 2 doses of the BNT162b2/BNT162b2 vaccine, neutralizing titer in Omicron was ~100x folds more significant in 3 individuals.  Arora et al. (2022) https://www.nature.com/articles/s41423-022-00870-5Sec1	Pokay DB	https://www.nature.com/articles/s41423-022-00870-5#Sec1
E484K, N501Y	S	False	pharmaceutical_effectiveness	 Out of 10 individuals with 3 doses of the BNT162b2/BNT162b2/BNT162b2 vaccine, neutralizing titer in Omicron was ~17.5x folds more significant in 9 individuals.  Arora et al. (2022) https://www.nature.com/articles/s41423-022-00870-5Sec1	Pokay DB	https://www.nature.com/articles/s41423-022-00870-5#Sec1
K417N, Q493H, N501Y	S	False	pharmaceutical_effectiveness	 100% of the 5 8â€‘monthâ€‘old male R3P1-E4 antibody treated mice suvived 14 days after infection while only 60% the control group mice survived 5 days post infection.   Li et al. (2022) https://link.springer.com/content/pdf/10.1186/s13578-022-00794-7.pdf	Pokay DB	https://link.springer.com/content/pdf/10.1186/s13578-022-00794-7.pdf
K417N, Q493H, N501Y	S	False	pharmaceutical_effectiveness	 Lung viral loads were tested by qRTâ€‘PCR and RNA scope at 3 dpi on 5 8â€‘monthâ€‘old male mice and there was a ~2266x fold drop in the R3P1-E4 antibody in comparison to   the IgG control.  Li et al. (2022) https://link.springer.com/content/pdf/10.1186/s13578-022-00794-7.pdf	Pokay DB	https://link.springer.com/content/pdf/10.1186/s13578-022-00794-7.pdf
K417N, Q493H, N501Y	S	False	pharmaceutical_effectiveness	 Trachea viral loads were tested by qRTâ€‘PCR and RNA scope at 3 dpi on 5 8â€‘monthâ€‘old male mice and there was a ~750x fold drop in the R3P1-E4 antibody in comparison to   the IgG control.  Li et al. (2022) https://link.springer.com/content/pdf/10.1186/s13578-022-00794-7.pdf	Pokay DB	https://link.springer.com/content/pdf/10.1186/s13578-022-00794-7.pdf
E484K, N501Y	S	False	pharmaceutical_effectiveness	 Infectious viral titers in lung tissue determined using a tissue culture infectious dose (TCID) assay in 10 hamsters showed that Omicron MK-4482 had no statistically   significant change.  Rosenke et al. (2022) https://insight.jci.org/articles/view/160108/pdf	Pokay DB	https://insight.jci.org/articles/view/160108/pdf
R346K	S	False	pharmaceutical_effectiveness	 This individual mutation, which has emerged in some Omicron sequences, has a 0.7x reduction in   neutralization activity with Sotrovimab in a VSV model on Vero E6 cells.   [Omicron sequences with R346K may very well have a non-additive neutralization rather than 2.7x+0.7x = 3.4x]  Cathcart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9
G446V	S	False	pharmaceutical_effectiveness	 This individual mutation found in the epitope from Sotrovimab causes a 1.5x reduction in  neutralization efficacy using a VSV model on Vero E6 cells.  Cathcart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9
G339D	S	False	pharmaceutical_effectiveness	 This individual mutation found in the epitope from Sotrovimab causes a 1.2x reduction in  neutralization efficacy using a VSV model on Vero E6 cells.  Cathcart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9
N440K	S	False	pharmaceutical_effectiveness	 This individual mutation found in the epitope from Sotrovimab causes a 0.7x reduction in  neutralization efficacy using a VSV model on Vero E6 cells.  Cathcart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9
S477N	S	False	pharmaceutical_effectiveness	 This individual mutation found in the epitope from Sotrovimab causes a 2.0x reduction in  neutralization efficacy using a VSV model on Vero E6 cells.  Cathcart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9
P681H	S	False	pharmaceutical_effectiveness	 This individual mutation found in the epitope from Sotrovimab causes a 0.9x reduction in  neutralization efficacy using a VSV model on Vero E6 cells.  Cathcart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.09.434607v9
F490S	S	False	pharmaceutical_effectiveness	 Greater than 10-fold rediuction of binding effeiency vs wild type for mAb LY-CoV555.  Rappazzo et al. (2021) https://doi.org/10.1126/science.abf4830	Pokay DB	https://doi.org/10.1126/science.abf4830
N440D, Y489H, Q493K, N501Y	S	False	pharmaceutical_effectiveness	 This Spike pseudotype for Day 146 virus from a chronically infected patient was completely resistent to REGN10933.  The variant had a 4-fold decrease in REGN10987 neutralization sensitivity (2nd component of the Regeneron mAb cocktail).  Clark et al. (2021) https://dx.doi.org/10.1016%2Fj.cell.2021.03.027	Pokay DB	https://dx.doi.org/10.1016%2Fj.cell.2021.03.027
Q493K	S	False	pharmaceutical_effectiveness	 Leads to a 14-fold reduction in neutralization efficiency for REGN10933.  Clark et al. (2021) https://dx.doi.org/10.1016%2Fj.cell.2021.03.027	Pokay DB	https://dx.doi.org/10.1016%2Fj.cell.2021.03.027
E484A, F486I, Y489H, N501Y	S	False	pharmaceutical_effectiveness	 This Spike pseudotype for Day 152 virus from a chronically infected patient was completely resistent to REGN10933.  Clark et al. (2021) https://dx.doi.org/10.1016%2Fj.cell.2021.03.027	Pokay DB	https://dx.doi.org/10.1016%2Fj.cell.2021.03.027
K417N, E484K, N501Y	S	False	pharmaceutical_effectiveness	 This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1  Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1"
K417T, E484K, N501Y	S	False	pharmaceutical_effectiveness	 Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from P.1.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
L452R	S	False	pharmaceutical_effectiveness	 Bamlanivimab (LY-CoV555) entirely lost its neutralizing activity due to the central location of  L452R in the epitopes recognized by this mAb.  Regdanvimab (CT-P59), and to a smaller extent etesevimab, showed a reduction in neutralization potency.  McCallum et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1  Bamlanivimab (LY-CoV555) lost ~5x binding against this isolated mutation.  Cligavimab lost ~4x binding against this isolated mutation.  Regdanvimab lost ~4x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1;https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1"
E406W	S	False	pharmaceutical_effectiveness	 COR-101 lost ~6x binding against this isolated mutation.  Estesevimab lost ~40x binding against this isolated mutation.  Regdanvimab lost ~8x binding against this isolated mutation.  m396 lost ~10x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
K417N	S	False	pharmaceutical_effectiveness	 COR-101 lost ~6x binding against this isolated mutation.  Estesevimab lost ~100x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
K417T	S	False	pharmaceutical_effectiveness	 COR-101 lost ~16x binding against this isolated mutation.  Estesevimab lost ~16x binding against this isolated mutation.  m396 lost ~8x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
K444Q	S	False	pharmaceutical_effectiveness	 Cligavimab lost ~8x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
G446V	S	False	pharmaceutical_effectiveness	 Cligavimab lost ~16x binding against this isolated mutation.  Imdevimab lost ~16x binding against this isolated mutation (the only RBD variant to do so).  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
Y543F	S	False	pharmaceutical_effectiveness	 Bamlanivimab (LY-CoV555) lost ~4x binding against this isolated mutation.  Casirivimab lost ~300x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
A475V	S	False	pharmaceutical_effectiveness	 COR-101 lost ~50x binding against this isolated mutation.  Estesevimab lost ~8x binding against this isolated mutation.  Sotrovimab lost ~30x binding against this isolated mutation.  Tixagevimab lost ~15x binding against this isolated mutation.  m396 lost ~8x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
E484A	S	False	pharmaceutical_effectiveness	 Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
E484K	S	False	pharmaceutical_effectiveness	 Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation.  Casirivimab lost ~16x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
E484Q	S	False	pharmaceutical_effectiveness	 Bamlanivimab (LY-CoV555) lost ~20x binding against this isolated mutation.  Casirivimab lost ~4x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
F486K	S	False	pharmaceutical_effectiveness	 Casirivimab lost ~5x binding against this isolated mutation.  Estesevimab lost ~10x binding against this isolated mutation.  Regdanvimab lost ~10x binding against this isolated mutation.  Tixagevimab lost ~10x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
S494P	S	False	pharmaceutical_effectiveness	 Bamlanivimab (LY-CoV555) lost ~8x binding against this isolated mutation.  Regdanvimab lost ~32x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
N501F	S	False	pharmaceutical_effectiveness	 COR-101 lost ~8x binding against this isolated mutation.  Regdanvimab lost ~6x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
N501S	S	False	pharmaceutical_effectiveness	 Estesevimab lost ~6x binding against this isolated mutation.  m396 lost ~16x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
N501T	S	False	pharmaceutical_effectiveness	 Estesevimab lost ~12x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
N501Y	S	False	pharmaceutical_effectiveness	 COR-101 lost ~8x binding against this isolated mutation.  Regdanvimab lost ~6x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
A520S	S	False	pharmaceutical_effectiveness	 CR3022 (SARS-targeting mAb) cross-reactivity lost ~4x binding against this isolated mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
E484K, K417N	S	False	pharmaceutical_effectiveness	 Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation.  COR-101 lost ~160x binding against this double mutation.  Casirivimab lost ~16x binding against this double mutation.  Estesevimab lost ~32x binding against this double mutation.  Regdanvimab lost ~4x binding against this double mutation.  Tixagevimab lost ~12x binding against this double mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
N439K, Y453F	S	False	pharmaceutical_effectiveness	 COR-101 lost ~12x binding against this double mutation.  Casirivimab lost ~64x binding against this double mutation.  Cligavimab lost ~6x binding against this double mutation.  Estesevimab lost ~10x binding against this double mutation.  Imdevimab lost ~5x binding against this double mutation.  Regdanvimab lost ~8x binding against this double mutation.  Sotrovimab lost ~4x binding against this double mutation.  Tixagevimab lost ~12x binding against this double mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
Y453F	S	False	pharmaceutical_effectiveness	 Casirivimab lost >50x binding against this mutation.  Hoffman et al. (2021) https://dx.doi.org/10.1016%2Fj.celrep.2021.109017	Pokay DB	https://dx.doi.org/10.1016%2Fj.celrep.2021.109017
S477N, E484K	S	False	pharmaceutical_effectiveness	 Bamlanivimab (LY-CoV555) lost ~10x binding against this double mutation.  Tixagevimab lost ~16x binding against this double mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
N501Y, E484K	S	False	pharmaceutical_effectiveness	 Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation.  COR-101 lost ~50x binding against this double mutation.  Casirivimab lost ~250x binding against this double mutation.  Estesevimab lost ~16x binding against this double mutation.  Regdanvimab lost ~32x binding against this double mutation.  Tixagevimab lost ~10x binding against this double mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
N501Y, K417N	S	False	pharmaceutical_effectiveness	 COR-101 lost ~20x binding against this double mutation.  Estesevimab lost ~16x binding against this double mutation.  Regdanvimab lost ~6x binding against this double mutation.  M396 lost ~10x binding against this double mutation.  Engelhart et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1
E156G, F157del, R158del	S	False	syncytium_formation	 Using ACE2-GFP+Spike-RFP fluorescence assay, this NTD+RBD mutation combination from B.1.617.3 did not affect syncytium formation.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
E156G, F157del, R158del, L452R	S	False	syncytium_formation	 Using ACE2-GFP+Spike-RFP fluorescence assay, this NTD+RBD mutation combination from B.1.617.3 increased syncytium formation ~2x.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
E156G, F157del, R158del, E484Q	S	False	syncytium_formation	 Using ACE2-GFP+Spike-RFP fluorescence assay, this NTD+RBD mutation combination from B.1.617.3 did not affect syncytium formation.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
E156G, F157del, R158del, L452R, E484Q	S	False	syncytium_formation	 Using ACE2-GFP+Spike-RFP fluorescence assay, this NTD+RBD mutation combination from B.1.617.3 increased syncytium formation ~2.5x.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
V367F	S	False	syncytium_formation	 Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
P384L	S	False	syncytium_formation	 Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
R408I	S	False	syncytium_formation	 Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
N501Y	S	False	syncytium_formation	 Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
N417N, N501Y	S	False	syncytium_formation	 ~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
E484K, N501Y	S	False	syncytium_formation	 ~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
D9L	S	False	trafficking	 According to the SignalP software, this mutation changes the predicted signal peptide for Spike from a suboptimal at S12 (as indicated by UniProt) or C15, to an optimal one at C15 only.  An optimal signal peptide may change the efficiency with which newly synthesized Spike migrates from ER-budded double-membrane vesicles (DMV) into the cytoplasm for trimer assembly.  Gordon (2021) unpublished	Pokay DB	
N856K	S	False	trafficking	 This mutation extends the fusion peptide 2 domain by 6 amino acids by substituting in a hydrophobic lysine. This may affect cell entry efficiency as the primary route of entry is cell membrane fusion.  Gordon (2021) unpublished	Pokay DB	
N501Y	S	False	trafficking	 This mutation alone accounts for most of the increased infectivity of the Alpha variant, as determined by modelling the infectivity  of each Spike mutation independently in a competitive infection model of hamsters, and Vero E6 (NHP) and Calu-3 (human) cell lines.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.08.434499v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.08.434499v1
P681H	S	False	trafficking	 In the absence of N501Y, this Alpha lineage change in the furin clevage site did NOT show significant increase in infectivity relative to wild type,   as determined by modelling the infectivity of each Spike mutation independently in a competitive infection model of hamsters.  Liu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.08.434499v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.08.434499v1
P681R	S	False	trafficking	 Quantification of the band intensities showed that the P681R mutation, which lies near the proteolytic processing site,   caused a small increase in proteolytic processing as measured by a 2-fold decrease in the ratio of S/S2.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1
V367F	S	False	trafficking	 ~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
P384L	S	False	trafficking	 ~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
R408I	S	False	trafficking	 ~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
N501Y	S	False	trafficking	 ~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
K417N, N501Y	S	False	trafficking	 ~5x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).   [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
E484K, N501Y	S	False	trafficking	 ~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).  [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
V367F	S	False	trafficking	 No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
P384L	S	False	trafficking	 No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
R408I	S	False	trafficking	 No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
N501Y	S	False	trafficking	 More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
N417N, N501Y	S	False	trafficking	 More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~13x, Vero ~10x, and Calu-3 ~10x. Compare to wild type at ~5x across cell types.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
E484K, N501Y	S	False	trafficking	 More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.  Kim et al. (2021) https://dx.doi.org/10.3390%2Fv13040633	Pokay DB	https://dx.doi.org/10.3390%2Fv13040633
N501Y	S	False	trafficking	 9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
E484K	S	False	trafficking	 ~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
K417N	S	False	trafficking	 ~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
K417N, N501Y	S	False	trafficking	 ~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
E484K, N501Y	S	False	trafficking	 ~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
E484K, K417N	S	False	trafficking	 Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
E484K, K417N, N501Y	S	False	trafficking	 ~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
N501Y	S	False	trafficking	 9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
E484Q	S	False	trafficking	 This variant alone shows a 10x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G.   Ferriera et al (2021) https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1
L452R	S	False	trafficking	 This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G.  [listed as L454R in Figure, but L452R in text, also text   suggests not statistically significant, but error bars say otherwise in Figure 4]  Ferriera et al (2021) https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1
L452R, E484K	S	False	trafficking	 This variant combination shows a ~4-5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G, same as L452R alone.  Ferriera et al (2021) https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1
E484K	S	False	trafficking	 This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G.   Ferriera et al (2021) https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1
L452R, E484K, P681R	S	False	trafficking	 This variant combination shows a ~3x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G,  significantly less of a decrease than any B.1.617 lineage variants alone, suggesting a synergistic effect on cell entry  while maintaining known immunity esacpe mutants.  Ferriera et al (2021) https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1
Y144del	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.1.7  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing slightly increased infection rate amongst the cells.   Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
N501Y	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.1.7  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing slightly increased infection rate amongst the cells.   [in what is essentially a replicate experiment in the same paper, because   each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,   a significant decrease was observed, therefore the error bars described in this paper  should be interpreted carefully]  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
A570D	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.1.7  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing statistically significant increased infection rate amongst the cells.   Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
P681H	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.1.7  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing NO statistically significant infection rate change amongst the cells, suggesting that  furin cleavage typically used for cell entry is not affected by this change one   amino acid upstream of the RXXR recognition pattern.   Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
T716I	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.1.7  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing major decrease in infection rate amongst the cells, hence this individual variant   is unlikely to contribute to cell entry fitness. T716I was expressed at significantly lower  level, accounting for the decreased infectivity of this spike protein.  This property may be specific to spike protein  biosynthesis in 293T cells and is not likely to reflect the situation in vivo given the reported  increase in infectivity of the B.1.1.7 virus.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
S982A	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.1.7  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing major (70%) increase in infection rate amongst the cells, hence this individual variant   is likely to significantly contribute to cell entry fitness.   Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
D1118H	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.1.7  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing mild decrease in infection rate amongst the cells, hence this individual variant   is unlikely to contribute to cell entry fitness.   Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, N501Y	S	False	trafficking	 Lentiviral pseudotyped with this mutation set from B.1.1.7  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing significant (40%) increase in infection rate amongst the cells, much more than the effect of   either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect   contributing to cell entry fitness, moreso than this combination with the addition of P681H.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, N501Y, P681H	S	False	trafficking	 Lentiviral pseudotyped with this mutation set from B.1.1.7  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing significant (40%) increase in infection rate amongst the cells, much more than the effect of   either the deletion or the point mutation alone, suggetsing that this combination has a synergistic effect   contributing to cell entry fitness, but to a smaller extent than N501Y and the deletion alone.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
L18F	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.351  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing mild decrease in infection rate amongst the cells, suggetsing that this   mutation does not contributing to cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
D80A	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.351  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing mild decrease in infection rate amongst the cells, suggesting that this   mutation does not contributing to cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
D215G	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.351  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing mild decrease in infection rate amongst the cells, suggesting that this   mutation does not contributing to cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
L242del	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.351  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing mild decrease in infection rate amongst the cells, suggesting that this   deletion does not contributing to cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
R246I	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.351  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing mild decrease in infection rate amongst the cells, suggesting that this   mutation does not contributing to cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
K417N	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.351  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing mild decrease in infection rate amongst the cells, suggesting that this   mutation does not contributing to cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
E484K	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.351  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing no change in infection rate amongst the cells.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
A701V	S	False	trafficking	 Lentiviral pseudotyped with this individual mutation from B.1.351  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing mild decrease in infection rate amongst the cells, suggesting that this   mutation does not contributing to cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
S477N	S	False	trafficking	 Lentiviral pseudotyped with the key mutations from 20A.EU2 lineage  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing no significant change in infection rate amongst the cells, suggesting that this   mutation does not contributing to cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
N501Y, Q677H	S	False	trafficking	 Lentiviral pseudotyped with the key mutations from COH.20G/677H lineage  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing no significant change in infection rate amongst the cells, suggesting that this   mutation does not contributing to cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, Y453F, I692V, M1229I	S	False	trafficking	 Lentiviral pseudotyped with all key mutations from Mink Cluster 5 lineage,  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing major (~50%) decrease in infection rate amongst the cells, suggesting that this   anthropozoonotic event is driven by other factors at the expense of human cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
Y453F	S	False	trafficking	 Lentiviral pseudotyped with this mutation from Mink Cluster 5 lineage,  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing modest decrease in infection rate amongst the cells, suggesting that this   variant does not contributing to human cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1  Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.  Motozono et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1"
I692V	S	False	trafficking	 Lentiviral pseudotyped with this mutation from Mink Cluster 5 lineage,  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing mild decrease in infection rate amongst the cells, suggesting that this   variant does not contributing to human cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
S1174L	S	False	trafficking	 Lentiviral pseudotyped with this mutation from Mink Cluster 5 lineage,  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing moderate decrease in infection rate amongst the cells, suggesting that this   variant does not contributing to human cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
M1229I	S	False	trafficking	 Lentiviral pseudotyped with this mutation from Mink Cluster 5 lineage,  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing slight decrease in infection rate amongst the cells, suggesting that this   variant does not contributing to human cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, Y453F	S	False	trafficking	 Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage,  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing slight decrease in infection rate amongst the cells, much closer to  D614G activity level than Y453F alone, suggesting compensatory effects between the   deletion and the mutation in human cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, Y453F, I692V	S	False	trafficking	 Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage,  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing moderate decrease in infection rate amongst the cells, significantly lower than the   deletion or Y453F alone, or their combination, suggesting a synergistic effect on   poorer human cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, Y453F, M1229I	S	False	trafficking	 Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage,  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing no change in infection rate amongst the cells, markedly higher infectivity than   either mutation alone, suggesting a synergistic net neutral effect on human cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, Y453F, S1147L	S	False	trafficking	 Lentiviral pseudotyped with this mutation set from Mink Cluster 5 lineage,  was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,   showing mild to modest decrease in infection rate amongst the cells, suggesting a net mild   negative effect on human cell entry fitness.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
N501Y	S	False	trafficking	 Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.  Motozono et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1
L452R	S	False	trafficking	 Increased stability of RBD expression in yeast, suggesting increased Spike protein stability.  Motozono et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1
P681H	S	False	trafficking	 This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance  cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious   Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage   (and presumably cell entry).  Maaroufi (2021) https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication  While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,   this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account   for the increased in transmission and disease severity attributed to this variant of concern (VOC).  Lubinski et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1	Pokay DB	"https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication;https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1"
P681R	S	False	trafficking	 This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance  cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious   Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage   (and presumably cell entry). [Inference from similar positively charged substitution P681H actually described in the work]  Maaroufi (2021) https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication	Pokay DB	https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication
L452R	S	False	trafficking	 We observed increased entry by pseudoviruses carrying the L452R mutation compared to D614G alone,   with a 6.7 to 22.5-fold increase in 293T cells and a 5.8 to 14.7-fold increase in human airway organoids.  Deng et al. (2021) https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1
W152C	S	False	trafficking	 Pseudoviruses carrying the W152C mutation demonstrated small increases in cell entry compared to   D614G alone in 293T cells and human airway organoids.  Deng et al. (2021) https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1
K417N, E484K, N501Y	S	False	trafficking	 The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were  about 3 to 4.4 times higher than that of the WT pseudovirus when viral input  was normalized, suggesting that these spike variants promote the infectivity of  SARS-CoV-2.  Hu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1
R815A	S	False	trafficking	 Mutation at the S2 internal fusion peptide site shown in vitro to reduce Spike subunit S2 cleavage into active S2'.  Barrett et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1
K814A, R815A	S	False	trafficking	 Mutation combination at the S2 internal fusion peptide site shown in vitro to reduce Spike subunit S2 cleavage into active S2'.  Barrett et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1
R685A	S	False	trafficking	 Mutation at the S1/S2 boundary site shown in vitro to reduce Spike cleavage (required for cell fusion and entry).  Barrett et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1
A831V	S	False	trafficking	 Circulating variant shown in vitro to not have major defects or  enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)  Barrett et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1
D839Y	S	False	trafficking	 Circulating variant near the internal fusion peptide shown in vitro to  reduce Spike subunit fusion required for cell entry.  Barrett et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1
D839N	S	False	trafficking	 Circulating variant near the internal fusion peptide shown in vitro to  reduce Spike subunit fusion required for cell entry.  Barrett et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1
D839E	S	False	trafficking	 Circulating variant shown in vitro to not have major defects or  enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)  Barrett et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1
S943P	S	False	trafficking	 Circulating variant shown in vitro to not have major defects or  enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)  Barrett et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1
P1263L	S	False	trafficking	 Circulating variant in the cytoplasmic tail, shown in vitro to increase Spike subunit fusion required for cell entry  Barrett et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1
S373P, E484A	S	False	transmissibility	 On December 7, 2021 the estimate of Omicron effective reproduction rate (Rt) is 3.12 [presumably R0 is higher],   compared to 1.12 for the dominant Delta VOC at that time. [shorthand of variant list shraed by all contemporary BA lineage used here]  Science Table (2021) https://web.archive.org/web/20211211220518/https://covid19-sciencetable.ca/ontario-dashboard/	Pokay DB	https://web.archive.org/web/20211211220518/https://covid19-sciencetable.ca/ontario-dashboard/
L452R, E484Q, P681R	S	False	transmissibility	 Normalized for particle number, on ACE2.293T cells  showed that the B.1.617 spike protein was >2-fold increase in  infectivity relative to D614G wild type.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1
Y145del, H146del, E484K	S	False	transmissibility	 Normalized for particle number, on ACE2.293T cells  showed that the B.1.618 spike protein was about as infective as D614G wild type.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1
L452R	S	False	transmissibility	 Increased infectivity of the B.1.617 spike was attributed to L452R, which itself caused a 3.5-fold increase in infectivity relative to D614G wild type.   [In combination with E484Q caused a somewhat less 3-fold increase]  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1  The L452R mutation increased the infectivity more than two-fold in these conditions.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1"
L452R, E484Q	S	False	transmissibility	 The combination caused a 3-fold increase in infectivity relative to D614G wild type. [compare to 3.5x for L452R alone]  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1
E484Q	S	False	transmissibility	 Using a pseudovirus assay, RBD-specific mutation E484Q did not significantly confer infectivity advantage to the spike particles.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
T19R	S	False	transmissibility	 Using a pseudovirus assay, this NTD mutation from B.1.617.3 did not confer an infectivity advantage to the spike particles.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
T95I	S	False	transmissibility	 Using a pseudovirus assay, this NTD mutation from B.1.617.3 did not confer an infectivity advantage to the spike particles.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
T19R, T95I	S	False	transmissibility	 Using a pseudovirus assay, this NTD mutation combination from B.1.617.3 did not confer an infectivity advantage to the spike particles.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
E156G, F157del, R158del	S	False	transmissibility	 Using a pseudovirus assay, this NTD mutation combination from B.1.617.3 conferred a nearly two-fold infectivity advantage to the spike particles.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
E156G, F157del, R158del, L452R	S	False	transmissibility	 Using a pseudovirus assay, this NTD+RBD mutation combination from B.1.617.3 conferred a ~2x infectivity advantage to the spike particles.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
E156G, F157del, R158del, E484Q	S	False	transmissibility	 Using a pseudovirus assay, this NTD+RBD mutation combination from B.1.617.3 conferred a ~4x infectivity advantage to the spike particles.  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
E156G, F157del, R158del, L452R, E484Q	S	False	transmissibility	 Using a pseudovirus assay, this NTD+RBD mutation combination from B.1.617.3 conferred a ~3x infectivity advantage to the spike particles   [less than L452R or E484Q alone working with the delins].  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
Q52R, E484K, Q677H, F888L	S	False	transmissibility	 The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other circulating strains in Denmark (early 2021).  Albertsen et al. (2021) https://www.covid19genomics.dk/2021-05-08_data-overview.htmlb1525	Pokay DB	https://www.covid19genomics.dk/2021-05-08_data-overview.html#b1525
N440K	S	False	transmissibility	 The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,   and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.   Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers   in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.  Tandel et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.30.441434v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.30.441434v1
S13I, W152C, L452R	S	False	transmissibility	" Exhibits an estimated 18.6-24% increase in transmissibility relative to wild-type circulating strains. a.k.a. 20C/L452R or B.1.427/B.1.429.  Deng et al. (2021) https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1  Lineages bearing these spike mutations comprised 54.4% of the total sequences from January, compared to 15.7% in November. Household   contacts exposed to the ""California"" or ""West Coast"" variants (B.1.427 and B.1.429) were at higher risk of infection compared   to household contacts exposed to lineages lacking these variants (0.36 vs 0.29, RR=1.28; 95% CI:1.00-1.64).  The reproductive number was estimated to be modestly higher than other lineages spreading in California during the second half of 2020.  Peng et al. (2021) https://doi.org/10.1093/cid/ciab283"	Pokay DB	"https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1;https://doi.org/10.1093/cid/ciab283"
K417N, E484K, N501Y	S	False	transmissibility	 Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13)  times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is  identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously  acquired immunity. Reality may lie between these extremes, with an intermediate increase in  transmissibility and mildly imperfect cross-protection from past exposure.   Pearson et al. (2021) https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf  36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021   in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant   transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in ÃŽle-de-France and 16.1 to 18.8% in Hauts-de-France).  This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.  Roquebert et al. (2021) https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1	Pokay DB	"https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1"
R408S, E484A, N501Y	S	False	vaccine_efficacy	 In a study of 481 vaccinees going from lowest to highest infection rate, 2 doses of CoronaVac and 1 dose of BNT162b2 had the lowest infection rate at 6.3%, then it  was 3 doses of BNT162b2 having a infection rate of 16.6%. 2 and 3 doses of CoronaVac had 48.6% and 20.6% infection rate respectively. 2 doses of BNT162b2 has   the highest infection rate at 49.2%.  Zhou et al. (2022) https://www.biorxiv.org/content/10.1101/2022.05.09.491254v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2022.05.09.491254v1
E484A, N501Y	S	False	vaccine_efficacy	 Pseudotyped virus neutralization demonstrated that Bi-Nab35B5-47D10 can efficiently neutralize VBMs including Alpha (B.1.1.7), Beta (B.1.351) and Kappa   (B.1.617.1) and VOCs including Delta (B.1.617.2).  Yuan et al. (2022) https://www.biorxiv.org/content/10.1101/2022.05.11.491588v1.full.pdf  In a Belgian study including 1,433,135 persons (vaccinated between July 2021 to April 2022) infection-acquired immunity offered additional protection   against symptomatic infection with Omicron in vaccinated persons compared to those without previous infection, when the infection was up to one year previous.  Braeye et al. (2022) http://doi.org/10.1101/2022.05.09.22274623v1  In sera from 17 sero-positive blood donors, and 18 months post-infection (May 2020) sera from 17 health   care workers in Sweden, a 40x drop in neutralization by Omicron (B.1.1.529) pseudotyped lentivirus   was observed in HEK293T cells using the First WHO International Standard (20/136). Median IC50 reduction  was ~6x for the blood donors, and ~4.5x for the health care workers.  Sheward et al. (2021) https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view	Pokay DB	"https://www.biorxiv.org/content/10.1101/2022.05.11.491588v1.full.pdf;http://doi.org/10.1101/2022.05.09.22274623v1;https://drive.google.com/file/d/1CuxmNYj5cpIuxWXhjjVmuDqntxXwlfXQ/view"
E484K, N501Y	S	False	vaccine_efficacy	 Protection against symptomatic infection caused by Beta/Gamma (assumed by combined presence of N501Y and E484K) was also higher with partial   vaccination for mRNA-1273 (77%) than BNT162b2 (60%) and ChAdOx1 (48%), and full vaccination increased effectiveness for BNT162b2 (84%).  Nasreen et al. (2021) https://www.medrxiv.org/content/10.1101/2021.06.28.21259420v2	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.06.28.21259420v2
L5F, S477N, E484K, A701V	S	False	vaccine_efficacy	 In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 114 test-positive were Iota.  Two dose vaccine efficacy against Iota was 95.7 (81.7-99.0%), one dose VE was 88.8 (0.7-98.7)%.  Bruxvoort et al. (2021) https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v1
L452R	S	False	vaccine_efficacy	 In a 1:5 test-negative matched control study of 8153 individuals who received the Moderna mRNA-1273 vaccine, 583 test-positive were Epsilon.  Two dose vaccine efficacy against Epsilon was 97.6 (90.2-99.4%), one dose VE was 76.3 (48.1-89.1%).  Bruxvoort et al. (2021) https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.09.29.21264199v1
N501Y	S	False	vaccine_efficacy	 In this Canadian test-negative study of 324033 individuals, two doses of either mRNA vaccine (BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna))   was not associated with appreciable vaccine escape by lineage Alpha [defined here as N501Y positive, but E484K negative].  Chung et al. (2021) https://doi.org/10.1136/bmj.n1943	Pokay DB	https://doi.org/10.1136/bmj.n1943
E484K	S	False	vaccine_efficacy	 In this Canadian test-negative study of 324033 individuals, two doses of either mRNA vaccine (BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna))   was not associated with appreciable vaccine escape due to E484K [given Dec 2020-Apr 2021 time frame of the study, this is assumed to entail both   Beta and Gamma lineages].  Chung et al. (2021) https://doi.org/10.1136/bmj.n1943	Pokay DB	https://doi.org/10.1136/bmj.n1943
E484K, N501Y	S	False	vaccine_neutralization_efficacy	 Log10ID50 of Omicron neutralizing antibodies is 0.722x the WT pre-third dose of pfizer-BioNTech BNT162b2 in  13 Kidney transplant recipients (KTR) with median age of 55.5.  McEvoy C et al. (2022) https://doi.org/10.1101/2022.06.24.22276144	Pokay DB	https://doi.org/10.1101/2022.06.24.22276144
E484K, N501Y	S	False	vaccine_neutralization_efficacy	 Log10ID50 of Omicron neutralizing antibodies is 0.686x the WT 1 month post-third dose of pfizer-BioNTech BNT162b2 in 13 Kidney transplant recipients (KTR) with median age of 55.5.  McEvoy C et al. (2022) https://doi.org/10.1101/2022.06.24.22276144	Pokay DB	https://doi.org/10.1101/2022.06.24.22276144
E484K, N501Y	S	False	vaccine_neutralization_efficacy	 Values taken 28 days after booster dose was given for BBIBP-CorVvaccine to 390 participants with 130 participants in the 0-14d-10m, 0-21d-10m and 0-28d-10m group. The geometric mean titers (GMT) of neutralizing antibody in 0-28d-10m and 0-21d-10m group were significantly higher than 0-14d-10m group at month 3, month 6 and month 10 after the second dose. A sharply decrease by 4.85-fold (GMT: 94.4-20.3), 4.67-fold (GMT: 134.4-28.8) and 4.49-fold (GMT: 145.5-32.4) was observed from day 28 to month 10 after the second dose in 0-14d-10m, 0-21d-10m and 0-28d-10m group, respectively, and they had similar decline kinetics.  Yao T et al. (2022) https://outbreak.info/resources/2022.06.22.22276690	Pokay DB	https://outbreak.info/resources/2022.06.22.22276690
E484K, N501Y	S	False	vaccine_neutralization_efficacy	 Omicron BA.4 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and   the Omicron variants still evade neutralization more efficiently.  Neerukonda et al. (2022) https://outbreak.info/resources/2022.06.01.494385	Pokay DB	https://outbreak.info/resources/2022.06.01.494385
E484K, N501Y	S	False	vaccine_neutralization_efficacy	 Omicron BA.5 neutralization of the Omicron variants by antibodies induced by three doses of Pfizer/BNT162b2 mRNA vaccine was 7-8-fold less potent than the D614G, and   the Omicron variants still evade neutralization more efficiently.  Neerukonda et al. (2022) https://outbreak.info/resources/2022.06.01.494385	Pokay DB	https://outbreak.info/resources/2022.06.01.494385
L452R	S	False	vaccine_neutralization_efficacy	 Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this RBD mutation conferred a 2.36x drop in neutralization (NT50).  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
E156G, F157del, R158del	S	False	vaccine_neutralization_efficacy	 Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD mutation conferred a 4.85x drop in neutralization (NT50).  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
E156G, F157del, R158del, L452R	S	False	vaccine_neutralization_efficacy	 Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD+RBD mutation combination from B.1.617.3 conferred a   7.42x drop in neutralization (NT50) [mostly from 3 of the sera].  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
E156G, F157del, R158del, E484Q	S	False	vaccine_neutralization_efficacy	 Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD+RBD mutation combination from B.1.617.3 conferred a   1.34x drop in neutralization (NT50) [mostly from a single serum].  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
E156G, F157del, R158del, L452R, E484Q	S	False	vaccine_neutralization_efficacy	 Using a pseudovirus assay and 6 ChAdOx1 vaccinee sera, this NTD+RBD mutation combination from B.1.617.3 conferred a ~3x drop in neutralization (NT50)   [working with the delins, less than just L452R but more than just E484Q].  Mishra et al. (2021) https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.10.04.463028v1
S13I, W152C, L452R	S	False	vaccine_neutralization_efficacy	 Mean 2.3x reduction of NT50 value B.1.427 (Epsilon) relative to wild type in 8 sera from adult BNT162b2 vaccinees (28-47yo) collected ~1m post booster.  Uriu et al. (2021) https://doi.org/10.1101/2021.09.06.459005	Pokay DB	https://doi.org/10.1101/2021.09.06.459005
L452R	S	False	vaccine_neutralization_efficacy	 Relative to B.1, Epsilon (B.1.417/429) shows 1.74x-2.35x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).  Wilhelm et al. (2021) https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.08.09.21261704v1
L452R, E484Q	S	False	vaccine_neutralization_efficacy	 Pseudotyped viruses for B.1.617 was 4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that  was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay.  Neutralization by 3 Moderna vaccine sera 28 days post-booster was 5-fold resistant (vs. 2.2-fold for B.1.351).  The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1  1.4x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1"
F157L, V367F, Q613H, P681R	S	False	vaccine_neutralization_efficacy	 Neutralization efficiency (ID50) against A.23.1-v1 reduced 1.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.  Choi et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1
E484K	S	False	vaccine_neutralization_efficacy	 Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that  was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay.  Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351).  The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1
R246I	S	False	vaccine_neutralization_efficacy	 On a B.1.351 background, this single mutation caused a mean 1.3 fold decrease in pseudotyped lentivirus neutralization.  Pegu et al (2021) https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1
E484K	S	False	vaccine_neutralization_efficacy	 Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)   against the variants containing the E484K substitution in the RBD were present but reduced   (fold reduction between 3.35â€“7.78, 95% confidence interval all above twofold difference, one-sample t test).   Solfrosi et al. (2021) https://doi.org/10.1084/jem.20202756	Pokay DB	https://doi.org/10.1084/jem.20202756
W152L, E484K, G769V	S	False	vaccine_neutralization_efficacy	" The estimated vaccine effectiveness against R.1 strain SARS-CoV-2 infection among residents in a Kentucky skilled nursing facility was   66.2% (95% CI = 40.5%â€“80.8%) and among health care workers was 75.9% (95% CI = 32.5%â€“91.4%) in the cohort of only those   14d+ post-vaccination Pfizer booster dose. VE against symptomatic COVID-19 was 86.5% (95% CI = 65.6%â€“94.7%) among residents   and 87.1% (95% CI = 46.4%â€“96.9%) among HCP. VE against hospitalization was 94.4% (95% CI = 73.9%â€“98.8%) among residents;   no HCP were hospitalized. Three residents died, two of whom were unvaccinated (VE = 94.4%; 95% CI = 44.6%â€“99.4%).  Cavanaugh et al. (2021) https://doi.org/10.15585/mmwr.mm7017e2"	Pokay DB	https://doi.org/10.15585/mmwr.mm7017e2
E484K	S	False	vaccine_neutralization_efficacy	 E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient   S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine   showed a mean 2.8x decrease in neutralization effiacacy.  Ikegame et al. (2021) https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1	Pokay DB	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1
N501Y	S	False	vaccine_neutralization_efficacy	" 1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine   at a dose of 100 Âµg (18-55 years; day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)   relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay.   Edara et al. (2021) https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1"	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1
K417N, E484K, N501Y	S	False	vaccine_neutralization_efficacy	 In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)  with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious   adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1   nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant.  Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination   showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This   RBD variant combination's neutralization by a placebo control   group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).  Madhi et al. (2021) https://doi.org/10.1056/NEJMoa2102214	Pokay DB	https://doi.org/10.1056/NEJMoa2102214
E484K	S	False	vaccine_neutralization_efficacy	 Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference   USA-WA1/2020 strain.  8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference   USA-WA1/2020 strain. One plasma failed to neutralize at all.  11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference   USA-WA1/2020 strain.   11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference   USA-WA1/2020 strain.   Jangra et al. (2021) https://doi.org/10.1016/S2666-5247(21)00068-9	Pokay DB	https://doi.org/10.1016/S2666-5247(21)00068-9
N501Y, K417N, E484K	S	False	vaccine_neutralization_efficacy	" In post-vaccination sera from individuals who received one (3 weeks post-first dose; n = 5) or two doses (9â€“11 days post-second dose;   n = 10) of the BNT162b2 Pfizer vaccine, an average 6.8x reduction in neutralization efficacy of this B.1.351 key variants pseudotype   lentivirus vs D614G was observed.  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008"	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
N501Y	S	False	vaccine_neutralization_efficacy	 This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
E484K	S	False	vaccine_neutralization_efficacy	 This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
K417N	S	False	vaccine_neutralization_efficacy	 This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
K417N, N501Y	S	False	vaccine_neutralization_efficacy	" This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose; n = 5) or two doses (9â€“11 days post-second dose;   n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008"	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
E484K, N501Y	S	False	vaccine_neutralization_efficacy	" This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose; n = 5) or two doses (9â€“11 days post-second dose;   n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008"	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
K417N, E484K	S	False	vaccine_neutralization_efficacy	" This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose; n = 5) or two doses (9â€“11 days post-second dose;   n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008"	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
K417N, E484K, N501Y	S	False	vaccine_neutralization_efficacy	" This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose; n = 5) or two doses (9â€“11 days post-second dose;   n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).  Kuzmina et al. (2021) https://dx.doi.org/10.1016%2Fj.chom.2021.03.008"	Pokay DB	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008
L452R, E484Q	S	False	vaccine_neutralization_efficacy	 Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range  of spike mutation bearing PV. E484Q had a ~5x drop in neutralization (vs ~10x for E484K). When  E484Q and L452R were combined, the fold change was significant, but similar to that of L452R alone (~2x),  suggesting no evidence for an additive effect [perhaps even E484Q effect dilution].   Ferreira et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1
E484K	S	False	vaccine_neutralization_efficacy	 Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range  of spike mutation bearing PV. E484K conferred a ten-fold reduction in  neutralisation by vaccine sera.  Ferreira et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1
L452R	S	False	vaccine_neutralization_efficacy	 Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range  of spike mutation bearing PV. L452R conferred about a two-fold reduction in  neutralisation by vaccine sera, but was not statistically significant with this sample size.  Ferreira et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1
E484K, F565L, V1176F	S	False	vaccine_neutralization_efficacy	 The study demonstrated 1.92 and 1.09 fold reductions (ELISA) in the neutralizing titer against B.1.1.28.2 (P2)  variant (n=2 authentic virus) in comparison with prototype D614G variant with 42 sera of BBV152 (a.k.a. Covaxin) vaccine recipients   2mo post-booster and 19 natural infections respectively.  [exact P.2 sequences were not given, using the common defining SNPs]  Sapkal et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.30.441559v1  Study 3001 on Ad26.COV2.S (Jannsen vaccine) conducted September 21, 2020 through January 22, 2021 overlaps the emergence and dominance   of the P.1 & P.2 lineages of SARS-CoV-2 in Brazil. The Brazilian arm of the Phase 3 double blind study showed severe/critical disease VE of 81.9%   (95% CI: 17.0-98.1), and moderate to severe/critical disease VE of 66.2% (95% CI: 51.0-77.1). Compare to 78.0% and 74.4% for North American arm  of the study during the same period (with low B.1.351 prevalence). Of the 69.3% of mostly severe infections sequenced as of this report, 69.4% were  of P.2 lineage [defining lineage SNPs reported here].  Janssen Biotech (2021) https://www.fda.gov/media/146217/download	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.04.30.441559v1;https://www.fda.gov/media/146217/download"
L5F, T95I, D253G, S477N, A701V	S	False	vaccine_neutralization_efficacy	" Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed no significant change in IC50 serum dilution concentration  for sera from BNT162b2 (Pzifer) or mRNA1273 (Moderna) vacinees collected 28 days following booster dose.  Zhou et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1  Neutralization efficiency (ID50) against B.1.526 reduced 2.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.  Choi et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1"	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1"
L5F, T95I, D253G, E484K, A701V	S	False	vaccine_neutralization_efficacy	" Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.6x reduction in both  IC50 serum dilution concentration for sera from 5 BNT162b2 (Pzifer) or 3 mRNA1273 (Moderna) vacinees collected 28 days following booster dose.  Zhou et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1  Detectable antibodies against B.1.526+E484K at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 43 100%, Day 209 88%.  Pegu et al (2021) https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1  2.3x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees)  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1"	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1"
P681H	S	False	vaccine_neutralization_efficacy	 No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7.  [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]  Zuckerman et al. (2021) https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1
S13I, W152C, L452R	S	False	vaccine_neutralization_efficacy	 Using HIV pseudotype: Neutralization potency of 11 Moderna mRNA1273-elicited plasma (7-27 days post-2nd dose) was  reduced ~2.8-fold compared to wildtype (D614G) S.   It was reduced ~4-fold in 14 Pfizer/BioNtech BNT162b2-elicited plasma (7-27 days post-2nd dose).   Using VSV pseudotype: we observed a 3-fold average reduction of Pfizer/BioNtech  BNT162b2-elicited plasma neutralizing activity.  McCallum et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.31.437925v1
H69del, V70del, Y453F, I692V, M1229I	S	False	vaccine_neutralization_efficacy	 Pseudotyped B.1.1.298 virus has reduced neutralization activity vs wild type: 1.4x (30 sera Pfizer median 9 days post 2nd dose)   and 1.3x (35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.  Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013	Pokay DB	https://doi.org/10.1016/j.cell.2021.03.013
S13I, W152C, L452R	S	False	vaccine_neutralization_efficacy	 Pseudotyped B.1.1.429 virus has reduced neutralization activity vs wild type: 2.0x (30 sera Pfizer median 9   days post 2nd dose, 35 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.  Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013  Detectable antibodies against B.1.1.7 in all samples at Day 43 and Day 209 using pseudotyped lentivirus neutralization in Moderna vaccinee cohort.  Pegu et al (2021) https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1  Neutralization efficiency (ID50) against B.1.1.427/429 reduced 2.1x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.  Choi et al. (2021) https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	Pokay DB	"https://doi.org/10.1016/j.cell.2021.03.013;https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1"
E484K, V1176F	S	False	vaccine_neutralization_efficacy	 Pseudotyped P.2 virus has reduced neutralization activity vs wild type: 5.8x (30 sera Pfizer median 9 days post 2nd dose)   and 2.9x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA.  Garcia-Beltran et al. (2021) https://doi.org/10.1016/j.cell.2021.03.013	Pokay DB	https://doi.org/10.1016/j.cell.2021.03.013
K417N, E484K, N501Y	S	False	vaccine_neutralization_efficacy	 Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)   against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.  Bates et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1
N501Y	S	False	vaccine_neutralization_efficacy	 Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)   against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.  Bates et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1  Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference   USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.  Rathnasinghe et al. (2021) https://dx.doi.org/10.1101%2F2021.01.19.21249592	Pokay DB	"https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;https://dx.doi.org/10.1101%2F2021.01.19.21249592"
L452R, N501Y	S	False	vaccine_neutralization_efficacy	 The presence of these B.1.417/B.1.429 defining variants in 189 post-mRNA-vaccination COVID-19 cases  was proportionally in line with lineage prevalence in Northen California during the study period,  suggesting no effect of these variants on immune escape.  Jacobson et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2
L452R	S	False	vaccine_neutralization_efficacy	 The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases  was proportionally in line with lineage prevalence in Northen California during the study period,  suggesting no effect of these variants on immune escape.  Jacobson et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2
N501Y	S	False	vaccine_neutralization_efficacy	 The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases  was proportionally in line with lineage prevalence in Northen California during the study period,  suggesting no effect of these variants on immune escape.  Jacobson et al. (2021) https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2
S13I, W152C, L452R	S	False	vaccine_neutralization_efficacy	 6 of 11 (55%) vaccine recipients (Moderna or Pfizer), showed 2x reduction in neutralization to a B.1.429 lineage virus.  Deng et al. (2021) https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1
S13I, W152C, L452R, L938F, K1191N	S	False	vaccine_neutralization_efficacy	 PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster   were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed no significant CD4+ cell count effect for CAL.20C (B.1.429),   and a slight decrease in CD8+ percentage (p=0.0201) by Activation Induced Marker (AIM) assay (cellular immunity measurement).   No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.  Tarke et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1
E484K	S	False	vaccine_neutralization_efficacy	 In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,   ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
N501Y	S	False	vaccine_neutralization_efficacy	 In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,   a modest decrease in neutralization by vaccine plasma was observed.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2
K417N, E484K, N501Y	S	False	vaccine_neutralization_efficacy	 In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,   a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.  Wang et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2  In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,   titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.  Wu et al. (2021) https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1	Pokay DB	"https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1"
E484K, N501Y	S	False	vaccine_neutralization_efficacy	 The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with   the BNT162b2 mRNA vaccine. (Fig. 4)  [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P=0.8774)]  Chen et al. (2021) https://doi.org/10.1038/s41591-021-01294-w  In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization.  This variant combination showed the highest reduction, but the magnitude of the differences was small   compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.  Xie et al. (2021) https://doi.org/10.1038/s41591-021-01270-4	Pokay DB	"https://doi.org/10.1038/s41591-021-01294-w;https://doi.org/10.1038/s41591-021-01270-4"
K974P, V975P	S	False	vaccine_specific_variants	" Tandem proline variants introduced at the edge of the central domain in viral class I fusion proteins  to increase vaccine antigen yield and stabilize the spike protein into the soluable pre-fusion (""3 down"") confirmation.  Pallesen et al. (2017) https://doi.org/10.1073/pnas.1707304114  In the paper describing the Moderna vaccine, the engineered mutations are described as K986P;V987P relative to their   Spike construct, but this maps differently in the reference sequence.  Corbett et al. (2020) https://doi.org/10.1038/s41586-020-2622-0"	Pokay DB	"https://doi.org/10.1073/pnas.1707304114;https://doi.org/10.1038/s41586-020-2622-0"
R670G, R671S, R673S, K974P, V975P 	S	False	vaccine_specific_variants	" In the Medicago vaccine candidate (CoVLP), the S protein was modified with R667G, R668S and R670S  substitutions at the S1/S2 cleavage site to ""increase stability"" (also, prevent furin cleavage), and K971P and V972P  substitutions to stabilize the protein in prefusion conformation. Coordinates remapped from construct to reference.  Ward et al. (2020) https://www.medrxiv.org/content/10.1101/2020.11.04.20226282v1"	Pokay DB	https://www.medrxiv.org/content/10.1101/2020.11.04.20226282v1
H69del, V70del	S	False	vaccinee_plasma_binding	 1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
Y144del	S	False	vaccinee_plasma_binding	 1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
N501Y	S	False	vaccinee_plasma_binding	 1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
A570D	S	False	vaccinee_plasma_binding	 No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
P681H	S	False	vaccinee_plasma_binding	 1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T716I	S	False	vaccinee_plasma_binding	 1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
S982A	S	False	vaccinee_plasma_binding	 2x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D1118H	S	False	vaccinee_plasma_binding	 1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L18F	S	False	vaccinee_plasma_binding	 1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   Compare to varied binding in full Spike variant complements for major lineages  containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma).  1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Compare to varied binding in full Spike variant complements for major lineages  containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D80A	S	False	vaccinee_plasma_binding	 1.64x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.35x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D215G	S	False	vaccinee_plasma_binding	 1.79x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L242del, A243del, L244del	S	False	vaccinee_plasma_binding	 1.43x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
R246I	S	False	vaccinee_plasma_binding	 1.05x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.45x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
K417N	S	False	vaccinee_plasma_binding	 1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
E484K	S	False	vaccinee_plasma_binding	 1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
A701V	S	False	vaccinee_plasma_binding	 1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T20N	S	False	vaccinee_plasma_binding	 1.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.39x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
P26S	S	False	vaccinee_plasma_binding	 1.23x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D138Y	S	False	vaccinee_plasma_binding	 1.37x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.56x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
R190S	S	False	vaccinee_plasma_binding	 1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.59x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
K417T	S	False	vaccinee_plasma_binding	 1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
H655Y	S	False	vaccinee_plasma_binding	 1.04x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.09x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T1027I	S	False	vaccinee_plasma_binding	 1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L5F	S	False	vaccinee_plasma_binding	 1.23x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
T95I	S	False	vaccinee_plasma_binding	 1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
D253G	S	False	vaccinee_plasma_binding	 No significant change in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L5F, T95I, D253G, E484K, A701V	S	False	vaccinee_plasma_binding	 This variant combination (representing lineage B.1.526) showed a 1.34x increase in Spike binding (relative   to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
S13I	S	False	vaccinee_plasma_binding	 1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.27x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
W152C	S	False	vaccinee_plasma_binding	 1.03x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.   1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
L452R	S	False	vaccinee_plasma_binding	 1.05x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.16x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
S13I, W152C, L452R	S	False	vaccinee_plasma_binding	 This variant combination (representing lineage B.1.429 aka Epsilon) showed a 1.1x decrease in Spike binding   (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  [Stark contrast to 2.15x increase in binding by convalescent plasma 8 months post infection, presumably via memory B cell affinity maturation   against L452R effects]  1.12x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
"L452R, E484Q	"	S	False	vaccinee_plasma_binding	 This variant combination (representing lineage B.1.617) showed a 1.30x decrease in Spike binding (relative   to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.    1.18x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.  [exact variant list not provided in manuscript, is inferred fro common knowledge]  Gong et al. (2021) https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1
E484K, N501Y	S	False	viral_load	 Venkatakrishnan et al. (2022) https://outbreak.info/resources/2022.06.03.22275976	Pokay DB	https://outbreak.info/resources/2022.06.03.22275976
E484K, N501Y	S	False	viral_load	 Viral load from oral swabs from 11 hamsters in 10 treatments for Omicron MK-4482 had the greatest drop 3 days post-infection determined by quantitative RT-PCR   targeting sgE in comparison to Alpha MK-4482, Beta MK-4482 and Delta MK-4482.  Rosenke et al. (2022) https://insight.jci.org/articles/view/160108/pdf	Pokay DB	https://insight.jci.org/articles/view/160108/pdf
E484K, N501Y	S	False	viral_load	 Viral load from lung tissue from 11 hamsters in 10 treatments for Omicron MK-4482 had the greatest drop 3 days post-infection determined by quantitative RT-PCR   targeting sgE in comparison to Alpha MK-4482, Beta MK-4482 and Delta MK-4482.  Rosenke et al. (2022) https://insight.jci.org/articles/view/160108/pdf	Pokay DB	https://insight.jci.org/articles/view/160108/pdf
L452R, E484Q, P681R	S	False	viral_load	 In 9 infected hamsters each for B.1 and B.1.617.1, no significant change in viral load or subgenomic RNA levels were detected.   Yadav et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.05.442760v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.05.442760v1
S13I, W152C, L452R	S	False	viral_load	 Swab samples N/NP viral RNA is approximately 2-fold higher in B.1.427/B.1.429 than in non-variant viruses.  Deng et al. (2021) https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1	Pokay DB	https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1
K417N, E484K, N501Y	S	False	viral_load	 The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase   (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26).   Teyssou et al. (2021) https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1  B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.  Roquebert et al. (2021) https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2	Pokay DB	"https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1;https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2"
F392W, Y365F	S	False	virion_structure	 This mutation combination stabilize the RBD-ACE2 binding interface, leading to a 3.8â€“5.3Â°C melting temperature increase relative to wild type.   [Relevant for thermostable vaccine antigen design]  Ellis et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.15.444222v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.15.444222v1
F392W	S	False	virion_structure	 This mutation stabilizes the RBD-ACE2 binding interface, leading to a 1.9â€“2.4Â°C melting temperature increase relative to wild type.  [Relevant for thermostable vaccine antigen design]  Ellis et al. (2021) https://www.biorxiv.org/content/10.1101/2021.05.15.444222v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.05.15.444222v1
P681H	S	False	virion_structure	 The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,   due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production  by improved proteolytic processing.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
P681R	S	False	virion_structure	 The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,   due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production  by improved proteolytic processing. [PG: Inferred by conservative AA substitution of described P681H]  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
A570D	S	False	virion_structure	 The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,   due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production  by improved proteolytic processing.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, N501Y	S	False	virion_structure	 The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,   due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production  by improved proteolytic processing.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
H69del, V70del, N501Y, P681H	S	False	virion_structure	 The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation combination,   due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production  by improved proteolytic processing.  Tada et al. (2021) https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1
L18F, D80A, L242del	S	False	virion_structure	 The L18F and D80A of the B.1.351 lineage lead to reconfiguration of the N-terminal segment despite the disulfide between  Cys16 and Cys136 that partly anchors the N-terminal peptide. The most consequential changes are probably from the triple residue deletion...  which causes a shift of the nearby loop 144-155 and must also reconfigure the adjacent disorder  loop (residues 246-260), both of which form part of the neutralizing epitopes...bringing large changes in the antigenic surface in this  region.  Cai et al. (2021) https://www.biorxiv.org/content/10.1101/2021.04.13.439709v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.04.13.439709v1
T1027I	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is 1.51 kcal/mol (i.e. stabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
D215G	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is 0.98 kcal/mol (i.e. stabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
H655Y	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is 0.87 kcal/mol (i.e. stabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
N501Y	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
D138Y	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is 0.43 kcal/mol (i.e. stabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
R246I	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is 0.33 kcal/mol (i.e. stabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
S477N	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is 0.22 kcal/mol (i.e. stabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
D80A	S	False	virion_structure	 Estimated that there is no free energy change (ddG) for this variant (i.e. same stability as wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
A570D	S	False	virion_structure	 Estimated that there is very little free energy change (ddG. -0.02 kcal/mol) for this variant (i.e. approx. same stability as wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
A701V	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is -0.33 kcal/mol (i.e. destabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
E484K	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
K417T	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is -0.64 kcal/mol (i.e. destabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
L452R	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is -0.67 kcal/mol (i.e. destabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
R190S	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is -0.69 kcal/mol (i.e. destabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
K417N	S	False	virion_structure	 Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type)   Spratt et al. (2021) https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1	Pokay DB	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1
